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The rise in obesity rate has drastically increased over the last few decades and has 
quickly grown into a worldwide epidemic. Large increases in visceral adipose tissue 
accumulation increase risk for metabolic disorders including insulin resistance, type 2 
diabetes, and cardiovascular diseases. Currently, increased levels of circulating non-
esterified fatty acids (NEFA) have been suggested to be the mediator linking obesity and 
type 2 diabetes. Studies identifying ways to alleviate mobilization of NEFA in adipose 
tissue via dietary phytochemicals may useful as a therapeutic approach. Despite the 
established benefits of resveratrol in health and in the development of obesity, the role of 
resveratrol metabolites in lipid metabolism remains unknown.  
The objectives of this study were to determine the role of resveratrol metabolites 
in adipose function with a focus on the effect in lipolysis and lipogenesis. Resveratrol 
metabolite, piceatannol, previously demonstrated its role as an antilipolytic agent through 
the suppression of lipolysis via protein degradation of adipose triglyceride lipase (ATGL) 
and comparative gene identification-58 (CGI-58). We hypothesized other resveratrol 
metabolites exhibit similar effects in modulating the lipolysis process. In our study, we 
examined several resveratrol metabolites and identified trans-   -trimethoxy 
resveratrol (TMR) having ability to suppress lipolysis in basal and stimulated conditions 
in mature murine adipocytes at non-cytotoxic levels. Upon further mechanistic studies, 
TMR at 50 µM reduces ATGL and CGI-58 protein expression with greatest efficacy in 
an acute, three hour treatment. mRNA expression analysis displayed that TMR may also 




the role of TMR in lipogenesis in maturing preadipocytes. Although TMR did not display 
significant reductions in lipid accumulation during lipogenesis, gene expression profiling 
indicates it may induce transcriptional remodeling of adipocyte function. Of interest, 
TMR upregulates expression of genes involved in mitochondria function suggesting 
increased catabolic processes, thermogenesis, and potential enhanced capacity for energy 
expenditure during development. Collectively, our study provides evidence that TMR, a 
resveratrol metabolite, might have a therapeutic potential in attenuating adiposity and its 








CHAPTER 1. REVIEW OF THE LITERATURE 
1.1 Introduction 
The rise in obesity rate has drastically increased over the last 30 years and has 
quickly grown in to worldwide epidemic (Rosen and Spiegelman 2006; Van Gaal et al. 
2006). Obesity, a disease of excess body fat, has attracted more attention due to the 
influence it has on regulation of overall energy homeostasis and coordinated responses 
(Rosen and Spiegelman 2006). Individuals with large visceral (central) adipose tissue 
deposition have elevated risk for metabolic disorders, morbidity, and mortality (Van Gaal 
et al. 2006). The large energy imbalance seen in obesity can be attributed to a variety of 
different factors including environmental, genetic, and metabolic function of central 
tissues (Kim et al. 2013).  
Currently, investigations identifying the role of phytochemicals on human health 
is being done, however there is less work examining the modulation obesity via action by 
phytochemicals (Kim et al. 2013). The role of natural bioactive components have been 
shown to have a wide range of action in signaling pathways and cellular functions (Kim 
et al. 2013). In this review of the literature, several molecular pathways involved in 
adipose function and lipid metabolism are outlined in regards to the development of 
obesity and its associated metabolic disorders. Additionally, dietary compounds, 
specifically resveratrol metabolites, are defined and examined as a potential therapeutic 
strategy in specific adipocyte functions related to the development of obesity and its 
associated diseases. Taken together, this review offers a central background of 
information for further understanding concerning the selected research goals and 




Obesity is defined as an excess accumulation of body fat to the ration of lean 
body mass. Obesity is determined with a numerical value of body mass index (BMI) of 
30 or greater (CDC 2012). BMI is calculated with a formula based on weight in 
kilograms divided the height of adult in meters (CDC 2011). Although obesity is 
commonly associated with extreme body weight, it is a heterogeneous group of 
conditions which have compounded by multiple causes and determined by genetics, 
environmental factors, energy intake and expenditure, and culture (Kopelman 2000). 
Until recently, obesity has only been considered a metabolic condition, and primarily 
isolated to developed western civilization. However within the 20th century, global 
increases in body weight have been on the rise in developing countries as well (Caballero 
2007). Changes in global food systems have caused a complex issues resulting in 
overnutrition and the promotion of obesity meanwhile nearly one billion people are 
malnourished (Swinburn et al.). The World Health Organization estimated that in 2008, 
1.4 billion adults were overweight and 500 million obese (WHO 2013). Over the last two 
decades, the rapid rise in obesity rate in the United States has drastically increased to an 
astonishing level of more than one-third the population , 35.7% , with 17% of adolescents 
and children, who are obese (Ogden et al. 2014). The development of obesity and 
increased adiposity is coupled with physiological changes in function and in the 
distribution of adipose tissue. With contribution by obesogenic factors, obesity expansion 
is caused by increased intake of energy-dense foods, reduced physical activity, with 
increases in sedentary lifestyles. The imbalance between energy intake and energy 
expenditure over time results in positive energy balance with increased energy stores, as 
adipose mass, and weight gain (Bleich et al. 2011). 
The American Medical Association recently recognized obesity as a disease 
which now requires medical interventions and is altering the way the medical community 
treats the complex issue and other chronic illness related to obesity (Breymaier 2013). 
Obesity is associated with many other metabolic disorders including cardiovascular 
disease, type 2 diabetes, inflammation, and certain cancers (Despres and Lemieux 2006). 
Also widely seen with excess fat accumulation is a composite of metabolic syndrome; a 
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combination of health issues that is largely seen with visceral obesity which is not 
exclusive to hyperlipidemia, insulin resistance, high blood pressure, and hypertension 
(Despres and Lemieux 2006). Moreover, obesity has also been reported as the underlying 
cause of sleep apnoea and sleep-related strokes which can lead to pulmonary 
hypertension, heart and respiratory failure (Kopelman 2000). Not only does the obesity 
rate cause a threat to global health, there is causation of severe financial implications. A 
conservative estimate for US national healthcare expenditures was estimated at $3.5 
trillion in 2012, and that number is projected to increase to $5 trillion by 2020 (CMS 
2010; 2014) with $150 billion attributed solely to obesity (Finkelstein et al. 2009). 
Defining strategies to alleviate not only the medical affliction of the obesity epidemic, but 
also the financial spending magnitude are imperative. It has been reported that modest 
weight loss can help to reduce risk factors for obesity associated diseases (Ben-
Menachem 2007; NIH 2005). Nonetheless, of the 51% of Americans who desire to lose 
weight, less than half are actively working to shed pounds (Brown 2013). Therefore, 
identifying therapeutic approaches is critical to help prevent or treat obesity and its 
associated metabolic disorders. 
 
1.3 Adipose biology 
Adipocytes play a critical role in whole body energy homeostasis and metabolism. 
Adipose tissue stores fatty acids (FA) in the efficient form of triglycerides via 
esterification to glycerol, and in times of excess energy expenditure or an energy shortage, 
it releases them into circulation (Galic et al. 2010). There are two types of adipose tissue: 
white and brown adipose tissue (BAT), each containing specific physiological roles 
(Mohamed-Ali et al. 1998). White adipose tissue (WAT) is the primary adipose tissue 
depot in humans and is largely characterized by unilocular adipocytes with single lipid 
inclusion used for storage and mobilization (Ahima and Flier 2000). Excess energy is 
stored as triacylglycerides in adipose tissue and can increase in tissue volume through 
increases in size of an adipocyte lipid droplet (LD), hypertrophy, and in number of 
adipocytes, hyperplasia, or both (Spiegelman and Flier 1996). In adults, most expansion 
of adipocytes occurs from increased LD size in adipocytes due to tight regulation of the 
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number of fat cells, holding constant throughout adulthood in lean and obese individuals 
(Spalding et al. 2008). Although, changes in body weight are primarily due to increase 
ad  	
       	  		           
hyperplasia, and induces the conversion of preadipocytes to adipocytes. Therefore, after 
losing body weight, it can be particularly hard to maintain a lean weight due to the 
constant number of adipocyte cells (Arner and Spalding 2010). 
Adipose tissue is a complex, active, and essential metabolic endocrine organ 
comprised of two-thirds adipocytes, and one-third connective tissue, nerve tissue, 
stromovascular cells, and immune cells. The traditional idea of adipose tissue solely used 
for energy storage is no longer relevant, as it has been widely studied for its metabolism 
and endocrine functions (Kershaw and Flier 2004). Adipose tissue is responsible for 
secreting endocrine, paracrine, and autocrine signals which include a range of proteins 
termed adipokines and lipoprotein regulators; such as leptin, tumor necrosis factor-
(TNF-  	
 -6 (IL-6), adiponectin, resistin, lipoprotein lipase, cholesterol ester 
transfer protein, and apoliporotein E (Mohamed-Ali et al. 1998). Adipokines participate 
in a variety of metabolic action via physiological processes which include inflammation 
and immune health (Lago et al. 2007). Overall, excess accumulation of adipose tissue 
poses a public health threat as whole body health and metabolism is affected and 
negatively effecting longevity and reduceing life expectancy (Olshansky et al. 2005). 
Moreover, identifying therapeutic strategies to specific adipose tissue targets may have 
large potential in curbing obesity and its associated syndromes.  
 
1.4 Adipogenesis 
Adipocytes are derived from multipotent mesenchymal stem cells which allow 
them to have a two-step process in becoming mature adipocytes (Rosen and MacDougald 
2006). This process begins with commitment to the adipocyte lineage followed by 
induction of terminal differentiation (Otto and Lane 2005). The first step of determination 
results in a preadipocyte that has lost its ability to differentiate into other cell lines. 
Widely used and accepted as a model for adipocyte biology include 3T3-L1 cells, 
originally clonally isolated from Swiss 3T3 mouse embryos (Green and Kehinde 1975; 
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Green and Meuth 1974; Gregoire et al. 1998). Preadipocytes are morphologically similar 
to that of fibroblasts and expansion of preadipocytes via hyperplasia occurs until 
confluence, when appropriate induction of differentiation causes the cell to acquire 
characteristics of mature adipocytes (Rosen and MacDougald 2006). In order for the 
differentiation process to occur, there are several steps that are completed, including 
development and growth arrest, allowance of mitogenic and adipogenic signals, and 
biochemical transformation, shown in Figure 1.1. Induction of differentiation in 3T3-L1 
cell culture requires a cocktail of hormonal stimulation that is given to cells comprising 
of dexamethasone (DEX), methylisobuthylxanthine (MIX), and insulin. Mitotic clonal 
expansion (MCE) occurs unique to non-primary preadipocytes which permits one or two 
more rounds of DNA replication. Terminal differentiation is accompanied by a 
transcriptional cascade which creates a distinctive spherical shape and accumulates LDs 
(Gregoire 2001; Gregoire et al. 1998; Otto and Lane 2005).  
 
1.4.1 Preadipocyte development, growth arrest, and differentiation 
In order to differentiate, preadipose cell lines which have proliferated and display 
a fibroblastic morphology are required to reach a level of confluence (Gregoire et al. 
1998; Hausman et al. 1980; Reichert and Eick 1999). The physical contact of cells results 
in growth arrest at which point preadipocyte cells withdraw from the cell cycle to 
undergo adipose conversion. It has been noted that cell to cell contact is not a sole 
requirement for this conversion into adipocytes, as it has been observed that cells plated 
at low density still maintain and go through differentiation (Gregoire 2001; Gregoire et al. 
1998). Pre-confluent proliferation and growth arrest are necessary for preadipocytes to 
experience the appropriate morphological and distinct gene expression before their 
transformation to adipocytes.  
Subsequent to growth arrest, preadipocytes must receive signals to further their 
development through differentiation which allow them to make specific biochemical 
alterations. CCAAT/enh  	 























specific adipocyte genes (Gregoire et al. 1998). Nonetheless, normal preadipocytes 
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maintain high levels of preadipocyte factor-1 (pref-1), C/EBP homologous protein 
(CHOP-10), and GATA transcription factors until they are down-regulated upon 
differentiation (Mei et al. 2002; Tang and Lane 2000; Tong et al. 2000). Pref-1 is a 
transmembrane protein inhibitor of adipogenesis (Mei et al. 2002), and is highly abundant 
in the stromal-vascular fraction of preadipocytes yet absent in mature adipocytes (Smas et 
al. 1999). Growth arrested preadipocytes express CHOP-10 which is responsible for 
  	
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	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Habener 1992; Tang and Lane 2000). GATA-2 and GATA-3 transcription factors bind 
specifically to DNA sequences, and are found in high levels in WAT and solely 
expressed in preadipocytes (Tong et al. 2000). Inherent expression of both represses 
differentiation in adipocytes, however with induction of differentiation these factors are 
down-regulated (Tong et al. 2005).  
In order for these transcription factors to be expressed, cells are stimulated to 
differentiate with a standard adipogenic mixture supplemented to fetal bovine serum 
(FBS) containing medium including the glucocorticoid DEX, cyclic adenosine 
monophosphate (cAMP)-phosphodiesterase inhibitor MIX, and a high dose of insulin 
(Macdougald and Lane 1995; Rosen and Spiegelman 2000; Sadowski et al. 1992). It is 
important to note that different cell models require diverse cocktails for the induction of 
differentiation due to the nature of the reagents used (Gregoire 2001). In 3T3-L1 cell 
linage culture, this standard mix is used to induce the cells to begin their transformation 














(Hajduch et al. 1995; Wu et al. 1996), 
meanwhile blunting the expression of Pref-1 (Smas et al. 1999). MIX heightens 
differentiation by increasing cAMP levels and through the downstream actions of the 








(Cao et al. 1991). 
Insulin is required for efficient differentiation of adipocytes because it not only increases 
the amount of lipid accumulation, but also it reduces apoptotic activity through insulin-
like growth factor-I (IGF-I) (Kiess and Gallaher 1998). Insulin action in differentiation is 
via cross-activation of IGF-I receptors inducing downstream signaling, stimulating many 
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adipogenic effects (Rosen and Spiegelman 2000). Taken together, MIX, DEX, and 
insulin create favorable conditions for 3T3-L1 cells to undergo morphological and 
metabolic changes during differentiation to allow for cytoplasmic lipid accumulation 
(Zhou et al. 1992).  
 
1.4.2 Mitotic clonal expansion 
Once differentiation has occurred in growth arrested cells at G0/G1 cycle, they are 
able to return to the cell cycle for one or two more rounds of DNA replication and cell 
doubling; a progression known as MCE (Tang et al. 2003). MCE occurs approximately 
24 hours after differentiation has been induced and is thought to be a necessary process to 
allow for the unwinding of DNA, subsequently allowing access for transcription factors 
to begin appropriate regulatory responses for the development of a mature adipocyte 
phenotype (Ntambi and Kim 2000). This DNA replication during mitosis also alters the 
promoter control elements helping to activate regulatory genes which initiate 
differentiation (Cornelius et al. 1994). However, whether MCE is truly required for 
differentiation has been deemed controversial; yet studies have identified evidence 
showing it is a prerequisite and that certain proteins acting as checkpoints for mitosis are 
important in the regulation of adipogenesis (Otto and Lane 2005; Rosen and MacDougald 
2006). Insulin was able to induce MCE solely, similarly to when 3T3-L1 cells are 
induced into the differentiation process through an adipogenic cocktail (Qiu et al. 2001). 
Certain growth proteins are essential during clonal expansion and include retinoblastoma 
proteins such as pRB, p107, p130 each which bind to E2F/DP resulting in an inactivation 
specific transcriptional growth factors (Gregoire et al. 1998). When there is inhibition of 
MCE in 3T3-L1 cells, differentiation of preadipocytes has been shown to be blocked 
(Nam et al. 2008). To note, cell division in primary adipocytes stemming from human 
adipose tissue is not a requirement when proceeding through differentiation. It is 
suggested that these specific type of cells have previously experienced the necessary cell 
divisions in vivo, and are already in the late stage of adipocyte development (Entenmann 




1.4.3 Adipogenic transcriptional cascade 
Necessary communication of extracellular signals by differentiating adipocytes to 
the nucleus give rise to the introduction of a transcriptional cascade (Gregoire et al. 1998). 


















differentiation (Rosen and MacDougald 2006). These factors trigger terminal 
differentiation and commitment of cells to the adipocyte lineage (Dani 1999). These 
changes compound a result of morphological changes and developed fat droplets.  
 
1.4.3.1 PPAR family 


      

  fffifi  fl
-dependent transcription factors 
that bind the ligand of receptors leading to activation of a target gene (Kersten et al. 
2000). PPARs behave similar to hormone receptors in which they bind the promoter 
region of a specific gene and form a heterodimer with retinoid X receptor (RXR), which 
results in activation responses in transcription when bound to the ligand hormone 
(Kersten et al. 2000)ffi 
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adipose, brown adipose, liver, kidney, heart, and skeletal muscle (Kersten et al. 2000). 









are transcribed from the same gene only with different splicing and promoters (Otto and 
Lane 2005)ffi 



































and its early binding in the differentiation process is required for the development of 









in transcription of genes in FA uptake, storage, and specifically adipocyte P2 (aP2), 
lipoprotein lipase, acyl-coenzyme A synthase and others (Otto and Lane 2005). It has 


















ability to go through adipogenesis (Wu et al. 1999b), as well as having no formation of 



























































adipose tissue mass and mouse embryonic fibroblasts resulted in impaired adipogenesis. 
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however they maintained normal levels of adipose mass and morphology (Rosen and 
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of its regulatory transcriptional activity (Spiegelman and Flier 1996; Tontonoz et al. 
1994). In 3T3-L1 cell culture model, its activity has been aptly demonstrated and shown 
to increase with insulin (Hu et al. 1995). Additionally, overexpression of the adipokine, 
       	  fl (Attie and Scherer 
2009).  
 
1.4.3.2 C/EBP family 
The transcription factor family of C/EBPs contains a basic luecine zipper domain, 
allowing activation via homo-and hetero-dimerization (Gregoire et al. 1998). This 
dimerization is a criterion for DNA-binding (Otto and Lane 2005). For the regulation of 
fl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fi (Yeh et al. 
1995). They are early regulators in the program of preadipocyte differentiation 
demonstrated by their ability to accelerate adipogenesis with protein overexpression, 
specifically in 3T3-L1 cells (Otto and Lane 2005). 
ffi !#
, though rapidly expressed 
after differentiation stimulators, does not possess the DNA binding ability until its 
phosphorylation occurs and it loses its association with CHOP-10, thus gaining DNA 
binding activity (Tang et al. 2004)* + ffi !#       
can participate in DNA binding after a 12 to 16 hour lag phase, simultaneously with the 
























initiate the transcription activation (Zhang et al. 2004). The transcriptional activators 
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day two of differentiation to approximately day five after differentiation induction 
(Ntambi and Kim 2000). To note, embryonic fibroblasts which did not contain both 
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ose tissue due to its ability to 
induce adipocyte genes directly (Rosen and MacDougald 2006)%     
contain C/EBP regulatory elements, and thereby can act as a positive feedback loop that, 
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(Tang et al. 2004)% 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metabolism, due to its modulation of adipocyte genes and encoding proteins specific to 
adipose tissue (Darlington et al. 1995)% ( 
























in liver, and in white and brown adipose tissues (Wang et al. 1995). In 3T3-L1 
preadipocytes, C/E








differentiate into mature adipocytes; demonstrating its important role in modulating 






 necessary for differentiation, it 
has been reported as sufficient to activate growth arrested cells without use of hormonal 
stimulation (Lin and Lane 1994)
%  	




thus early expression of this gene would inhibit preadipocytes from entering MCE, a 
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responses to maintain terminal differentiation (Spiegelman 1998).  
 
1.4.4 Terminal differentiation 
Terminal differentiation is a state in which adipocytes have largely increased in de 
novo lipogenesis and are sensitive to insulin (Gregoire et al. 1998). Cells are no longer 
participating in the cell cycle and lose their capacity to proliferate; although after 
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differentiation, preadipocytes may be able to de-differentiate and re-enter mitosis 
(Cornelius et al. 1994). Nonetheless, once cells have surpassed the GD point, they have 
become fully committed to terminal differentiation (Otto and Lane 2005). Observable 
changes take place with increased lipogenesis and LD formation. Mature adipocytes have 
lost their preadipocyte fibroblastic characteristics and appear spherical with the 
acquisition of biochemical and morphological traits of adipocytes (Macdougald and Lane 
1995). Cells have also increased in protein levels related to lipid metabolism and 
enhanced expression of adipose tissue specific products, such as aP2 and FA binding 
protein (FABP). Furthermore, lipogenic enzymes and adipokines are highly expressed 
including leptin, adiponectin, and resistin (Gregoire et al. 1998; Otto and Lane 2005).   
 
1.5 Lipogenesis 
Triacylglycerides (TAG) are made up of a glycerol backbone esterified with three 
FA chains. TAG synthesis activity in WAT is an imperative factor for determination of 
adipose tissue mass and the release of non-esterified FA (NEFA). As seen in fasting rats, 
approximately 57% of newly hydrolyzed FA were recirculated for TAG synthesis (Wang 
et al. 2008). Although FA mainly come from the diet, 1-2% are made in adipose tissue 
itself (Wang et al. 2008). The carbon movement from glucose to FA is highly regulated 
by lipogenesis and involves a series of enzymatic reactions (Ameer et al. 2014). During 
FA synthesis, the first step includes a series of conversion reactions of citrate to acetyl-
CoA by ATP-citrate lyase (ACL) (Ameer et al. 2014). Carbons coming from acetyl-CoA 
are added to a growing chain of FA. The key rate limiting step is ATP dependent on 
acetyl-CoA carboxylation to malonyl-CoA carboxylase 1 by acetyl-CoA carboxylase 1 
(ACC1) (Gathercole et al. 2013). Malonyl-CoA is then transformed by multiple steps into 
a 16 carbon FA, palmitate, by fatty acid synthase (FAS), the major enzyme accounting 
for FA biogenesis (Zaidi et al. 2013). Further reactions lead to the production of 
complicated FA originating from palmitate, resulting in de novo lipogenesis (DNL) 
products of palmitate, and small amounts of stearate and shorter FA (Ameer et al. 2014).  
Once FA have been generated by DNL, they are converted into substrates for 
TAG formation by becoming saturated and transformed into monounsaturated FA 
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(MUFAs) by stearoyl-CoA desaturase 1 (SCD1). SCD1 has preference to convert 
saturated stearate and palmitate to their MUFAs oleate and palmitoleate, respectively. 
SCD1 is a rate limiting reaction and its desaturase activity has been proposed to reduce 
FA oxidation and stimulate DNL (Hulver et al. 2005). Biogenesis of TAG is a series of 
esterification of FA moieties that are consecutively added to a glycerol backbone (Farese 
and Walther 2009). The acylation of a glycerol-3-phosphate and the first FA occurs by 
glycerol-3-phophate acyltransferase (GPAT) and the second by diacylglycerol 
acyltransferase (DGAT) yielding phosphatidic acid (PA), which is then dephosphorylated 
to produce diacylglycerol (DAG) (Gathercole et al. 2013; Kuerschner et al. 2008). DAG, 
by a third acylation, then becomes TAG, but could be used as a prerequisite for 
phospholipids. DGAT2, which is highly associated with adipocytes, is localized to the 
endoplasmic reticulum (ER) and is responsible for the catalyzed reaction into TAG 
(Kuerschner et al. 2008). Of the enzymes which are involved in TAG synthesis, they are 
commonly found in the ER as well as the mitochondria, or in mitochondrial-associated 
membranes and have different isoforms. Newly generated TAG have been suggested to 
be at large to go into an associated lipid bilayer and locating to cytosolic LD, or to cells 
which secrete TAG (Yen et al. 2008).  
The biogenesis of LDs are defined as the initial accumulation of neutral lipids 
tightly connected at the ER (Digel et al. 2010). LDs are linked to a wide variety of 
functions which include lipid storage, energy and membrane formation, and protein 
degradation. LD synthesis occurs de novo and are generated in the ER (Walther and 
Farese 2012). LDs are primarily comprised of an organic phase of TAG and sterol esters 
in the core, yet other neutral lipids are present such as free cholesterol and retinol ester 
(Thiele and Spandl 2008). However the majority of the volume in adipocytes is TAG. 
The initial step is followed a gathering of proteins and increased lipid synthesis to create 
a globular LD. LDs have been observed in contact with the ER when formed and the 
specific membrane associated proteins moved between the two complexes (Walther and 
Farese 2012). In periods of excess energy, TAG need to be stored in LD and allowance 
for growth in LD requires local coordinated TAG synthesis or a translocation from the 
ER. This involves large amounts of TAG being located to its core (Farese and Walther 
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2009). LD droplet formation include ER budding which allows LD to grow from the ER 
bilayer and then bud off (Walther and Farese 2012). The main thought is that TAG 
biosynthesis is done between the leaflets of the ER membrane, prior to budding off and 
forming a LD. It was demonstrated that TAG is synthesized near the surface of the LD, 
accordingly indicated LDs grow by influx. Thus LDs can grow in size with droplet to 
droplet fusion and via increasing TAG levels (Kuerschner et al. 2008).  
In adipose tissue, all the major lipogenic enzymes are present, however only low 
levels have been observed compared to rodents (Gathercole et al. 2013). The low levels 
of ACL, which produces cytosolic acetyl-CoA for FA synthesis, is suggested to be reason 
DNL in adipose tissue accounts for a small percentage of lipid generation (Gathercole et 
al. 2013; Wang et al. 2008). Nonetheless, DNL in vitro is regulated partly by hormones 
and the dysregulation of the lipogenic pathway can cause disruption to overall lipid 
metabolism and homeostasis (Ameer et al. 2014). 
 
1.6 Lipolysis 
LDs are a critical and active organelle found in the intracellular cytoplasm of 
many cells. Previously, adipose tissue and LDs were considered only inert storage 
locations for excess fat (Ahmadian et al. 2009). However in recent years, LD biology has 
been an increasing interest due to studies identifying proteins and mechanistic pathways 
specific to LDs and represent a progressive area in cell biology (Farese and Walther 2009; 
Walther and Farese 2012). Within the core of the LD, TAG, which are highly 
hydrophobic, reduced and concentrated, are used for storing energy, occupying much of 
the space in the cytoplasm (Farese and Walther 2009). Surrounding the LD is a 
phospholipid monolayer covered with proteins functioning to stabilize and regulate 
(Brasaemle 2007).  
The mobilization of the stored energy stems from lipolysis; the hydrolysis of TAG 
into NEFA and a single glycerol backbone (Zechner et al. 2012) as shown in Figure 1.2. 
Lipolysis is an absolute prerequisite for cellular uptake and of release of FA to and from 
the bloodstream, first observed by Whitehead in 1909 (Whitehead 1909). This catabolic 
process allows for NEFA to be released during fasting, in times of metabolic need, as 
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well as when TAGs are in a surplus amount (Zechner et al. 2012). Nonetheless, the 
process of lipolysis is an intricate phenomenon which orchestrates the use of cellular 
lipases, plasma membrane transporters, FA binding proteins, and LD associated proteins 
(Langin 2006a). This mobilization of NEFA from adipose tissue via lipolysis, can be 
released to enter the bloodstream and    	 
 
  
 -oxidation and 
further for ATP formation. NEFA may also be transported to the liver in order to be used 
as substrates for ketogenesis, and glycerol for gluconeogenesis (Ahmadian et al. 2010).  
 
1.6.1 Lipolytic cascade 
Lipolysis occurs in periods of increased energy demand or expenditure, and is 
activated by hormones (Zimmermann et al. 2004). The concentration of NEFA is highly 
regulated between a balance of triglyceride hydrolysis and NEFA esterification (Langin 
2006b). Hydrolysis points occur at the primary and secondary ester bonds between the 
FA and the glycerol backbone (Zimmermann et al. 2004). Adipocyte lipolysis occurs in a 
meticulous order of events and in a regulated fashion, with each step utilizing a different 
enzyme; sequentially adipose triglyceride lipase (ATGL), hormone sensitive lipase (HSL), 
and monoglyceride lipase (MGL) (Ahmadian et al. 2009; Walther and Farese 2012; 
Zechner et al. 2012). ATGL performing the initial cleavage of the first FA is the rate 
limiting step in which it transforms the TAG to form a diacylglyceride (DAG) and a 
NEFA. The second lipase, HSL, is a multifunctioning enzyme in that it has the capacity 
to hydrolyze TAG, DAG, and monoacylglyeride (MAG); its cleavage of FA from the 
acylesters contain a breadth (Lass et al. 2011). In fact, HSL was formerly thought to be 
the rate limiting lipase in TAG hydrolysis (Duncan et al. 2007), however, Haemmerle 
demonstrated through HSL knockout mice a shift in composition of fat: rather than 
accumulating TAG, KO mice increased in DAG levels, observably showing that HSL is 
primarily responsible for DAG hydrolysis (Haemmerle et al. 2002). Lastly, MGL 
removes the final FA, freeing the last NEFA and glycerol (Duncan et al. 2007; Lass et al. 
2011). This simple explanation for describing the lipolysis process is tightly regulated by 
a highly complex system of signals and mechanisms.  
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Increased levels of NEFA and glycerol in serum to be used as oxidative substrates 
are products of stimulated lipolysis (Duncan et al. 2007). Catecholamines are the major 
regulators in fasting induced lipolysis and are considered the starting point in the 
metabolic pathway that modulates TAG hydrolysis and NEFA release (Duncan et al. 
2007). Catecholamines are able to impact lipolysis once they bind to different 
adrenoceptor     	
   1-3 and 1-2, each linked to a G-protein (Jocken and Blaak 
2008). Norepinephrine, a catecholamine, binds to -adrenergic receptors, on the 
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3 is 
most active (Barbe et al. 1996; Jocken and Blaak 2008). The G-   s, then 
sends a signal to adenylyl cyclase (AC) which then activates the production of cAMP 
(Duncan et al. 2007). The increase in cAMP intracellular levels leads to the activation of 
a cAMP dependent protein kinase (PKA) (Carmen and Víctor 2006). Once cAMP binds 
PKA, this results in the controlling subunits to disassociate with the catalytically active 
stretch, thus increasing activity of the complex (Kim et al. 2005). This activation of PKA 
results in the phosphorylation of HSL and perilipin, a LD surface protein, and to further 
the catalysis of TAG to release NEFA and glycerol (Carmen and Víctor 2006) (Jocken 
and Blaak 2008). In addition, in the fasted state high levels of glucocorticoids also 
increase ATGL transcription and generate a signaling cascade (Villena et al. 2004). There 
are other signaling pathways which also induce lipolytic reactions in 3T3-L1 cells 
including protein kinase C and its stimulation by phorbol ester PMA in a dependent 
mitogen-activated protein kinase (MAPKs) and independent MAPK pathway (Carmen 
and Víctor 2006) ff	
  	     2-adrenoceptors that are coupled to 
inhibitory G-proteins (Gi). These Gis will inactive AC, thus reducing cAMP levels and 
muting PKA activity (Jocken and Blaak 2008).   
During a fed state, insulin acts as an antilipolytic agent via a regulatory pathway 
which involves both cAMP dependent and independent pathways (Duncan et al. 2007). In 
adipocytes, the cAMP dependent cascade involves insulin binding to its receptor which 
transmits a signal resulting in activation of phosphodiesterase 3B by phosphorylation, in 
turn degrading cAMP levels (Ahmadian et al. 2010). This reduction of cAMP levels 
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relieves PKA from activation and blunting the phosphorylation mediated activity of HSL 
and perilipin (Duncan et al. 2007). The cAMP independent modulating pathway by 
insulin is through the stimulating phosphorylation of protein phosphatase-1(PP-1) 
causing an alteration in its regulatory subunit. Activating phosphorylation of PP-1 results 
in the dephosphorylation and inactivation of HSL, reducing the lipolytic rate (Duncan et 
al. 2007; Razani et al. 1999). Insulin also has action in regulating the expression of 
ATGL; insulin has been shown in 3T3-L1 cells to down-regulate ATGL possibly through 
FoxO1 (Ahmadian et al. 2010; Kershaw et al. 2006).  
The physiological relevance of the controlling pathways of lipid metabolism is 
critical due to the volume of fat that is predominately found in adipose tissue (Jocken and 
Blaak 2008). Dysregulation of lipolysis and lipid metabolism can lead to severe 
physiological consequences. Specifically in a high fat diet-induced obesogenic state, 
there is increased basal lipolysis resulting in increased levels of circulating NEFA 
(Gaidhu et al. 2010). Defective regulation of lipolysis leads to excessive NEFA 
accumulation in visceral adipose tissue, and is highly correlated to insulin resistance 
which can result in impairment of the this hormone to act as an antilipolytic agent 
(Gaidhu et al. 2010). Overall, alternations in the regulation of this catabolic process can 




In 2004, three different groups identified a novel lipolytic enzyme which was 
responsible for TAG hydrolysis, and each gave the lipase a different name including 
ATGL (Zimmermann et al. 2004), desnutrin (Villena et al. 2004), and phospholipase A2 
(Jenkins et al. 2004). In the scope of this review, ATGL will be the name utilized. ATGL 
is a 54 kDa protein that has an N-terminal domain similar to patatin, a plant acyl 
hydrolase, which encompasses its catalytic activity that cleaves at the primary ester bond 
at sn-1(3) position (Duncan et al. 2007; Lass et al. 2011; Walther and Farese 2012). 
ATGL is tightly associated with the LD in differentiated 3T3-L1 cells and maintains a 
hydrophobic region for binding to the LD (Duncan et al. 2007); loss of this domain 
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results in loss of intracellular activity because of its inability to locate and bind the LD 
(Zechner et al. 2012). ATGL is considered to be the major lipase in adipose tissue 
lipolysis with its high substrate specificity to TAG (Ahmadian et al. 2010), showing 
minimal activity toward other lipids including DAG, MAG, cholesterylesters or 
retinylesters (Lass et al. 2006; Lass et al. 2011). The localization of ATGL has been 
determined, with the majority of ATGL locating in the cytoplasm (approximately 50%), 
yet a portion of it is found to be tightly associated to the LD, around 10% (Zimmermann 
et al. 2004). This amount of ATGL localized with the LD is not affected by the 
stimulation of lipolysis, with Zimmermann observing the co-localization to the LD in 
3T3-L1 cells (Zimmermann et al. 2004). In energy demand, increased levels of ATGL 
translocate from the cytosol to the surface of the LD upon activation (Bezaire et al. 2009). 
When ATGL is genetically altered in vivo, NEFA release by lipolysis was reduced 
greater than 75% in ATGL-deficient mice (Haemmerle et al. 2006; Haemmerle et al. 
2002).  
ATGL expression and enzymatic activity is tightly regulated. ATGL requires an 
activator protein which markedly increases its activity known as comparative gene 
identification -58 (CGI-    	
 ain containing protein 5 (ABHD5) 
(Zimmermann et al. 2009) (Lass et al. 2011). Through interaction of ATGL and CGI-58, 
maximum stimulation is seen at equal concentrations of both proteins (Lass et al. 2006). 
Studi 































#-58 interaction also 
occurs. The C-terminal end of the ATGL includes its regulatory function and location of 
its LD interaction (Lass et al. 2011). The activation of ATGL by CGI-58 is necessary for 
lipolytic action and acts independently of HSL (Bezaire et al. 2009). Another key 
regulator for ATGL involves its interaction with perilipins; proteins which are highly 
associated with LD surface, in which many are phosphorylated by AMP-dependent PKA 
upon lipolytic stimulation (Clifford et al. 1998). Studies identifying the complex system 
of how ATGL is activated as the initial step in lipolysis suggest CGI-58 and perilipins 
engage the enzyme and mediate ATGLs LD targeting and hydrolysis of TAG (Walther 
and Farese 2012). Hydrolytic activity of ATGL in fat cell lipolysis, in both the basal and 
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hormone stimulated conditions, to proceed is necessary and maintains as the first step in 
the sequential regulation of lipolysis (Lafontan and Langin 2009).  
Studies observed ATGL ablation in 3T3-L1 cells showed that with compromised 
lipolysis, cells were not able to compensate, even with the presence of other lipases 
(Duncan et al. 2007). ATGL-null mice have extreme TAG accumulation in the heart 
which resulted in premature heart failure (Brasaemle 2007), as well as reduced lipolysis 
which lead to fat deposition in many tissues, including fat, liver, muscle, kidney, spleen, 
and lung tissues (Lass et al. 2011). This has also been demonstrated with patients that 
contain ATGL gene mutations. Similar to ATGL null mice, there is massive TAG 
accumulation located in multiple tissues as well as the development of cardio myopathy, 
which is highly lethal (Lass et al. 2011). ATGL mediated TAG catabolism is an essential 
in all cells and when deficient, there is inability to maintain normal energy metabolism 
during fasting or energy expenditure (Lass et al. 2011). However, in studies analyzing the 
effect of high fat diet included obesity, there is disrupted signaling in the lipolytic 
cascade inducing upregulation of ATGL and its co-activator CGI-58. This results in 
increased basal lipolysis but blunted catecholamine-induced lipolysis yielding a 
dysfunctional mechanism, increased circulating NEFA, and contributing to obesity 
induced metabolic disease state (Gaidhu et al. 2010). 
 
1.6.3 HSL 
HSL was first discovered in the 1960s in which its isolation and characterization 
in adipose tissue demonstrated its innate ability to hydrolyze both DAG and TAG 
(Zechner et al. 2012). However, this 84 kDa cytoplasmic enzyme has a much greater 
affinity for DAG with relatively an eleven fold higher hydrolase activity toward DAG 
than TAG and preference for FA in the sn-1 or sn-3 position (Duncan et al. 2007; 
Lafontan and Langin 2009; Raclot 1997). Much of the recent knowledge of HSL stems 
from a study done with HSL-null mice, which demonstrated no changes in TAG 
accumulation in adipose tissues and nonadipose tissue, yet the level of DAG was 
enhanced (Haemmerle et al. 2002; Zechner et al. 2012). This led to the accepted thought 
that HSL is the second rate-limiting step in lipolysis and ATGL is responsible for initial 
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TAG hydrolysis. HSL also retains specificity to other lipid ester bonds such as 
cholesteryl esters, retinyl esters, and short-chain carbonic acid esters (Duncan et al. 2007; 
Zechner et al. 2012). The largest expression concentrations of HSL mRNA and protein 
include white and brown adipose tissues, although there is some low levels seen in other 
organs (Zechner et al. 2012). To date, there are three regions of HSL which make up its 
functional capacities including the N-terminal domain, C-terminal domain, and a third 
region presenting as the controlling component (Lafontan and Langin 2009). The N-
terminal region has been suggested as the modulator of lipid binding, dimerization of the 
enzyme, and interface with FA binding protein 4 (FABP4) (Lass et al. 2011). The action 
of HSL is increased by the presence of aP2 and FABP4, both which interact and aid in 
the movement to the surface of LD (Wang et al. 2008). The C-terminal domain contains a 
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(Lass et al. 2011; 
Yeaman 1990).  





  -adrenergic stimulation, HSL is the target of PKA 
phosphorylation and other kinases which regulate its enzymatic activity (Lass et al. 2011) 
(Zechner et al. 2012). HSL phosphorylation at 5 serine residue sites by PKA, AMPK and 
MAPK are a critical regulatory steps for hormone-induced lipolysis and increases HSL 
lipolytic activity (Zimmermann et al. 2009) (Walther and Farese 2012). Through overall 
modulation of cAMP levels, catecholamines and insulin levels play a role in the 
regulation of HSL action (Lafontan and Langin 2009). This phosphorylation also allows 
for the recruitment of HSL to the surface of the LD and increased HSL activity 100 fold 
(Schweiger et al. 2006). The regulation of HSL induces a two-step process of activation: 
PKA phosphorylates HSL at several serine sites (Ser81, Ser222, and Ser276) resulting in 
translocation from the cytosol to the LD and binds HSL to a perilipin adipose 
differentiation-related protein, and secondary phosphorylation of serine-660 (Ser660) is 
responsible for the imperative LD interfacial activation and hydrolysis (Walther and 
Farese 2012; Wang et al. 2009). The activation of the signaling kinase pathway which 
stimulates lipolysis via phosphorylating HSL at Ser660 has been demonstrated in vitro 
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(Greenberg et al. 2001). The lack of HSL greatly affects overall adipocyte function and 
the hydrolysis of DAG and release of NEFA (Zimmermann et al. 2009).  
 
1.6.4 MGL 
The final step in lipolysis is catalyzed by MGL, the rate-limiting point for 
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resultant after the intracellular TAG hydrolysis by ATGL and DAG by HSL, and occurs 
in the cytoplasm of the cell (Zechner et al. 2012). This 33 kDa lipase was found in 1975 
and purified from rat adipose tissue with its role clarified as the monoacylglyeride 
enzyme (Tornqvist and Belfrage 1976). MGL is responsible for cleaving the 1(3)- or 2- 
ester bonds of MAG, with specificity to only MAG, and no observed activity against 
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in a GXSXG motif, Ap239, and HIS 269; mutation at any of these sites results in 
complete ablation of its lipase ad esterase activity (Duncan et al. 2007; Lafontan and 
Langin 2009; Lass et al. 2011). MGL is highly expressed in adipose tissue, but has been 
seen in other tissues (such as kidney and testis), and has demonstrated its ability to 
degrade MAG has been studied intensively via mutant mouse models (Chanda et al. 2010; 
Lass et al. 2011; Zechner et al. 2012). Without MGL activity in adipose tissue the 
lipolysis process is compromised and increases in levels of MAG are observed (Zechner 
et al. 2012). Recently, a new role for MGL in endocannabinoid signaling has been 
suggested, yet more investigations to fully understand its role in regulating appetite, pain 
sensations, and mood control need to be addressed (Lass et al. 2011). Currently, the 
literature reveals that the activity of MGL is not dependent upon hormonal stimulation, 
but necessary for complete degradation of TAG in vitro (Zimmermann et al. 2009). MGL 
activity has not been observed as rate limiting due to the abundance of the enzyme. 
Nonetheless, it plays a pivotal role as a modulator of 2-acylglyerol level release of the 
final NEFA, and is the last, but necessary step for the lipolysis process (Chanda et al. 




Perilipins are proteins which are tightly associated with adipocyte LD at the 
surface (Clifford et al. 1998). There are three protein isoforms stemming from the 
translation of alternatively spliced mRNA. These include perilipin A, which the largest 
with 517 amino acids (AA) and found in high numbers on the surface of the LD in 
adipocytes; perilipin B, that shares 405 AA with perilipin A , and perilipin C (Brasaemle 
2007). Perilipin C is the shortest isoform of the three and is expressed solely in 
steroidogenic tissue cells (Brasaemle 2007).  
For lipolysis to occur, soluble lipases need to access a hydrophobic LD and begin 
action on the TAG substrate, and perilipin proteins are a prerequisite for their action and 
contact with the LD (Duncan et al. 2007). During lipolysis perilipins are highly 
phosphorylated and stimulated by PKA, alongside HSL. Perilipins which lack 
phosphorylation by PKA, act as a barrier to lipid lipases and protect against hydrolysis 
(Clifford et al. 1998). The primary LD associated protein that is present in mature 
adipocytes is perilipin A(1), both in differentiated 3T3-L1 cells and murine primary cells 
(Brasaemle et al. 2000) (Shen et al. 2009). Perilipin A is a member of the PAT family and 
regulates WAT breakdown by controlling ATGL and HSL via mediating activity (Lass et 
al. 2011). It is highly expressed in adipocytes and interacts with the LD, specifically at 
the three C-terminal hydrophobic stretch (these are able to penetrate the LD) (Walther 
and Farese 2012). At the surface of the LD, perilipin A contains an amphipathic area, 
which has been suggested to add to lipid binding (Walther and Farese 2012). In 
unstimulated conditions, ATGL and HSL are located at the surface of the LD and are 
seen up to 50%; perilipin A and B which coat the LD are the only functional barrier that 
inhibit their action (Brasaemle et al. 2000). Perilipin A, the greatest phosphorylated 
protein behind PKA, plays an imperative role in the modulation of both basal and 
stimulated lipolysis. This is demonstrated by increased basal lipolysis and perilipin null 
mice loss of PKA-stimulated lipolysis (Martinez-Botas et al. 2000; Shen et al. 2009). 
Simultaneous to HSL phosphorylation, PKA also phosphorylates perilipin A on six 
different serine residues (Shen et al. 2009; Wang et al. 2009; Zechner et al. 2012). 
Increased TAG storage and inhibition of lipolysis has been observed with increased 
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expression of perilipin A. Discovered in 3T3-L1 cells, preadipocytes subjected to 
perilipin A transfection showed large reductions in lipolytic rates and even larger 
increases in TAG storage (Brasaemle et al. 2000; Duncan et al. 2007). Perilipin proteins 
located on the LD are critical for PKA stimulation of HSL translocation, and has been 
shown to be necessary for maximal lipolysis (Miyoshi et al. 2006). The phosphorylation 
of perilipin by PKA may also enable interaction with HSL on the LD, thus increasing 
enzymatic activity (Duncan et al. 2007; Miyoshi et al. 2006). Perilipin, during fasting 
conditions, also allows for the recruitment of ATGL and CGI-58 to the LD via 
dissociation of CGI-58 from perilipin A and activation of ATGL (Ho et al. 2011) (Lass et 
al. 2011; Zechner et al. 2012). Although these proteins are not critical for LD 
establishment, they are necessary in regulating lipid metabolism (Walther and Farese 
2012). Overall perilipin A plays an important dual role in regulating lipolysis, first in 
preventing basal lipolysis and second upon PKA stimulation, increasing the process 
(Langin 2006a; Shen et al. 2009).  
 
1.7 NEFA 
Under normal conditions, NEFA have the ability to act as a fuel source alternative 
to glucose, occurring most often during times of fasting or increased energy expenditure 
(Unger 1995). In a fed state, insulin acts as an antilipolytic agent by suppressing NEFA 
levels and allowing glucose to be metabolized (Unger 1995). In obesity and type 2 
diabetes, plasma NEFA are elevated in these conditions due to their lack of suppression 
by feeding as a result of insensitivity to insulin by adipocytes or increase in adipocyte 
mass (Kahn et al. 2006; Unger 1995). Excess NEFA toxicity, along with reduced normal 
oxidative metabolism frequently results in ectopic fat accumulation in non-adipose 
  	
   	  -cell dysfunction, cardiomyopathy and hepatic steatosis; 
termed lipotoxicity (Weinberg 2006). Excess lipid accumulation in other tissues other 
than adipose tissue can result in severe metabolic complications, including insulin 
resistance, diabetes, coronary heart disease, and even heart failure (Listenberger et al. 
2003). Evidence has shown that increased circulating NEFA are contributors to this 
deposition to non-adipose tissues causing lipotoxicity and subsequent disorders 
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(Listenberger et al. 2003) as shown in Figure 1.3. Multiple pathways can be altered as a 
result of both acute and chronic effects of excess NEFA concentrations (Weinberg 2006). 
NEFA are imp      	
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dysfunction (Kahn et al. 2006).  
NEFA plasma concentrations are increased in an obesogenic condition and are 
highly indicative of the dysregulation of lipolysis (Lafontan and Langin 2009). Two 
components of lipolysis which could contribute to obesity include reduced plasma 
delivery from adipose tissue during energy expenditure or fasting, or impaired 
suppression of NEFA by insulin. The latter leads to the therapeutic potential of 
identifying antilipolytic agents due to the fact excessive lipolysis results in high 
circulating levels of NEFA and development of dyslipidemia and metabolic syndrome 
(Langin 2006a). Insulin mediated glucose uptake in cells as well glucose tolerance has 
been shown to improve upon acute action with an antilipolytic agents which helps to 
reduce NEFA levels (Kahn et al. 2006). It has been shown that cellular TAG 
accumulation is not toxic and in fact, accumulation in TAG pools of surplus NEFA, 
rather than locating to other pathways (in non-adipose tissues) that lead to cytotoxicity, 
act as a buffer against lipotoxicity (Listenberger et al. 2003). Thus, identifying 
antilipolytic agents which prevent lipolysis can be used as a therapeutic approach to 
avoid amplified NEFA levels all together.  
 
1.8 Lipolysis as a therapeutic target for metabolic disease 
With obesity, a state of sufficient increase in adipose tissue mass causing adverse 
health effects, dramatically increased, so has the amount metabolic disorders (Spiegelman 
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and Flier 2001). Metabolic syndrome is described as an array of contributing factors 
which negatively impact human health which includes insulin resistance, visceral (central) 
obesity, hypertension, a proinflammatory state, and increased circulating TAG and NEFA 
concentrations (Gertow et al. 2006). Obesity is associated with many metabolic 
syndromes, but specifically obesity results in an increase in basal levels of lipolysis, 
which can lead to insulin resistance (Duncan et al. 2007). Although basal lipolysis can be 
cut in half upon weight loss, often the desire to lose is greater than action taken (Brown 
2013; Reynisdottir et al. 1995). Insulin insensitivity in adipocytes is a contributing factor 
  	
 	 		 	  	 -adrenergic receptors to stimulated lipolysis are 
often compromised in an obese individual (Duncan et al. 2007). Increased levels of 
lipolysis results in enhanced levels of circulating NEFA which are highly correlated to 
harmful whole body metabolic effects as discussed above. 
There is therapeutic potential in regulating and manipulating lipolysis as a means 
to reduce levels of NEFA. In an obesogenic condition, multiple disorders can arise as a 
result of adipocyte lipolysis including ketogenesis, ketolysis, mitochondrial disease, and 
glycogen storage diseases (Wang et al. 2008). It was observed that both obese and non-
obese relatives of obese patients alike share in atypical lipolytic processes (Wang et al. 
2008). Lipolysis suppression could be very beneficial with inborn errors of fatty acid 
oxidation (FAO) and ketone metabolism (Wang et al. 2008). Altering lipolysis has large 
potential in re-balancing NEFA flux and regulating fat mass as a way to reduce the risk of 
obesity-induced complications in metabolic syndrome.  
Currently, identification of mechanisms and potential targets to develop anti-
obesity drugs are being done, many which relate to metabolic syndrome (Grundy 2006). 
Specifically in adipose tissue, there are metabolic pathways which could be significant in 
targeting as obesity contributors to metabolic syndrome conditions. However, drug 
development is in preliminary stages and remains to be safe and effective, especially if 
chronic use is needed with minimal side effects (Grundy 2006). Specifically, identifying 
compounds which inhibit lipolysis in an effort to lower serum levels of NEFA is a 
strategy to manage obesity associated diseases, like type 2 diabetes (Ahmadian et al. 
2010). Increased NEFA being released at higher rates than oxidative capacity can also 
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cause ectopic TAG storage and lipodystrophy; and chronic levels of NEFA in circulating 
plasma can have a lipotoxic effects (Ahmadian et al. 2010; Lass et al. 2006). Taken 
together a vicious cycle ensues with increased mobilization of NEFA from adipose tissue, 
typically suppressed by insulin, yet adipocytes that become insulin resistant, 
consequently lipolysis is further increased (Karpe et al. 2011). Therefore identifying was 
to alleviate lipolysis and NEFA release will in turn produce approaches to treat obesity-
induced metabolic syndromes.  
 
1.8.1 Lipolysis and cancer cachexia 
Lipolysis may also be involved in cancer-associated cachexia (Zechner et al. 
2012). Cancer cachexia is defined as an intricate metabolic syndrome commonly 
associated with illness and characterized by persistent erosion of body mass due to a 
malignant growth. It has also been termed as an auto-cannibalism or wasting disease 
(Evans et al. 2008). Also commonly associated with cancer cachexia is anorexia, 
inflammation, insulin resistance, anemia, and hypogonadism (Evans et al. 2008). This 
wasting disease is primary due to the involuntary loss of skeletal muscle and adipose 
tissue, which are the majority and best studied targets of cachexia (Beutler and Cerami 
1988). Typically, there are increased circulating factors that can induce lipolysis which 
include TNF-  -6 and zinc- -glycoprotein 1 (Zechner et al. 2012). TNF-   	

as a mediator of cachexia via its stimulation of adipocyte breakdown (Tracey et al. 1988). 
Cancer patients with cachexia have been observed to have higher activity of lipolytic 
enzymes, NEFA and glycerol levels, suggesting that lipolysis signaling is involved in the 
severe loss of adipose tissue and muscle. Although the fundamental mechanisms remain 
unknown, inhibition of lipolysis may play a role in helping to prevent or attenuate 
cachexia in people with cancer or other diseases (Evans et al. 2008; Zechner et al. 2012).  
 
1.9 Dietary intervention of obesity 
As the obesity epidemic continues to progress, there is large opportunity for 
functional ingredients that may be beneficial for weight control to be used in food 
product development (Kovacs and Mela 2006). Therefore, to establish a dietary 
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intervention strategy to combat obesity, a variety of factors need to be taken into 
consideration for practical feasibility. In addition, to mechanistic and clinical efficacy 
evidence, a proposed food ingredient should satisfy other criteria including safety, 
stability in processing and shelf life, raw ingredient quality and reliable sourcing, 
regulatory usage levels and dosing schedule, cost, and adequate and appealing food 
vehicle (Kovacs and Mela 2006). Bioactive components from food are attractive due to 
their extensive history of safe consumption as well as their health benefits, including 
weight control. The following focuses on dietary sources of functional components that 
help to prevent weight gain, aid in weight control, or reduce risk factors associated with 
excessive adipose mass.  
 
1.9.1 Role of phytochemicals in adipose function 
The potential for natural products to combat obesity is large due to the 
dissatisfaction of current anti-obesity drugs on the market (Yun 2010). Natural products 
that could be used to treat obesity include crude extracts or plant sourced isolated 
compounds. There have been many studies identifying and demonstrating the benefit of 
different dietary components in regards to their impact on energy balance (Astrup et al. 
2010). Specifically, research has aimed to improve our understanding how bioactive food 
component help to inhibit energy storage, reduce lipid uptake or formation, stimulate fat 
mobilization, or increase levels of fat oxidation via different mechanisms (Kovacs and 
Mela 2006).   
Adipocytes play a large role in overall homeostasis and energy balance by storing 
TAG and releasing NEFA based on energy demand as previously described. Studies have 
looked to identify anti-obesity biomaterials which inhibit adipocyte proliferation or 
differentiation (Yun 2010). However, contemporary research have suggested that 
inhibiting adipogenesis can be unhealthy and may lead to pathogenesis of type 2 diabetes 
or other metabolic diseases (Lefterova and Lazar 2009). Therefore pharmacological 
targeting of lipolysis has been investigated to help partially block the release of the 
already high levels of circulating NEFA in obesity and dyslipidemia. Many of the natural 
components which had been found to affect lipolysis do so by stimulation or activation of 
27 
 
the lipolytic pathway rather than reduce it. It was found that Nobiletin, a 
polymethoxylated flavone found in citrus fruits, dose-dependently stimulated lipolysis in 
3T3-L1 adipocytes through activation of cAMP/PKA pathway (Saito et al. 2007). Toona 
sinesis leaf extracts have also been shown to enhance lipolysis in differentiated 3T3-L1 
cells (Hsu et al. 2003). The aromatic compound of red raspberries, raspberry ketone, has 
the ability to increase norepinephrine induced lipolysis in white adipocytes through 
enhanced translocation of HSL to the surface of the LD (Morimoto et al. 2005). The hot 
water soluble extract of Salacia reticulata, which is a Hippocrateaceae plant, 
demonstrated stimulation of lipolysis in rat epididylmal adipocytes (Yoshikawa et al. 
2002). Oolong tea also has anti-obesity properties through its major bioactive component, 
caffeine, that acts on the lipolysis process via interactions with LD lipases (Han et al. 
1999; Yun 2010). In fact, caffeine and other methylxanthines stemming from tea and 
coffee are well characterized and known to stimulate lipolysis through increases in cAMP 
levels (Duncan et al. 2007). Flavonoids genistein, diadzein, coumestrol, and zeralenone 
all show a dose-dependent effect in enhancing lipolysis in rat adipocytes, along with 
quercetin, luteolin, and fisetin, imposing dose- and time-dependent increases (Rayalam et 
al. 2008a). Resveratrol, a highly studied polyphenol found in grapes, has also been 
studied in regards to its stimulatory effect on lipolysis through activation of ATGL (Lasa 
et al. 2012b). Ethanol contains acute antilipolytic effects resulting in reduced levels of 
FFA in serum as well as in chronic conditions adipocytes show s	 
 -
adrenergic receptor mediated lipolysis (Duncan et al. 2007; Kang et al. 2007). Of these 
dietary sources, most show an induction of lipolysis, and few food components have 
demonstrated an antilipolytic effect. 
 
1.10 Resveratrol and resveratrol metabolites 
 Resveratrol (trans--trihydroxystilbene) is a phytoalexin polyphenolic, 
naturally occurring compound that is produced in plants when there is a pathogenic attack 
or induced stress, not exclusive to fluctuations in climate, sunlight, and heavy metals 
(Athar et al. 2007; Fremont 2000). It is present in food such as berries, grapes, and 
peanuts and has many biological activities which include acting as an antioxidant, anti-
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inflammatory, neuroprotective, anti-aging, anti-cancer, and cardioprotective (Baur and 
Sinclair 2006; Fremont 2000; Wang et al. 2004). The efficacy of oral administration of 
resveratrol depends on absorption, metabolism, and tissue distribution, yet rapid 
metabolism generally leads to the production of sulfates and glucuronides (Baur and 
Sinclair 2006; Hoshino et al. 2010). Due to the nature of the breakdown, it has been 
suggested that the physiological significance of having increased concentrations of 
resveratrol, used in in vivo studies, more likely should be given to resveratrol metabolites 
and their effects (Hoshino et al. 2010), structurally shown in Figure 1.4. Levels of 
resveratrol are generally exceeded by resveratrol metabolites due to phase II metabolism 
and longer plasma half-life of its metabolites; resveratrol has a short plasma half-life 
while the metabolites can maintain a plasma half-life of 9.2 hours (Athar et al. 2007; 
Patel et al. 2010). Due to its rapid breakdown and extensive metabolism, there is a 20 
fold higher concentration of resveratrol conjugates which circulate, than resveratrol itself, 
equating to less than 1% (Andres-Lacueva et al. 2012). This is a major issue in 
  	
	  	   functional compound, and raises the 
question of the biological activities and the effect of resveratrol metabolites themselves 
(Lasa et al. 2012a). 
 Research that has investigated resveratrol and its metabolites in vivo has detected 
glucuronide and sulfate conjugates, with only a small amount of resveratrol that was left 
unaltered (Hoshino et al. 2010; Urpi-Sarda et al. 2005). For example, it was shown that 
with oral ingestion of 25 mg of dietary relevant resveratrol, plasma concentration 
detected was in the nanomolar range, whilst its metabolites maintained levels in the 
micromolar range (Calamini et al. 2010; Walle et al. 2004). It has also been reported that 
generally speaking, glucuronides have been the leading metabolite in rodents, whereas 
sulfates are more prevalent in human plasma (Burkon and Somoza 2008; Emilia Juan et 
al. 2010; Lasa et al. 2012a). After glucuronidation and sulfation of resveratrol in both the 
gut and liver, resveratrol metabolites are taken up dependently by ABC transporters 
(Kenealey et al. 2011). The distribution of the resveratrol metabolites also depends on 
specific location, the concentration delivered, and the species (Andres-Lacueva et al. 
2012). These facts suggest that if not most, some of the biological effects stimulated by 
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resveratrol should be attributed to its metabolites (Hoshino et al. 2010) and their activity 
(Wenzel and Somoza 2005). Furthermore, resveratrol metabolites have shown significant 
effects in biological activities (Lasa et al. 2012a).   
 Research identifying tissue distribution of resveratrol metabolites has primarily 
focused on profiling the liver, kidney, lungs, brain, and testis, however more recently, 
resveratrol metabolites were found located at intermediate levels in adipose tissue and 
even low levels in skeletal muscle (Andres-Lacueva et al. 2012). The majority 
investigations of resveratrol metabolites are researched in regards to their distribution and 
profile of their relative levels in tissues, with limited studies focusing their action. 
Resveratrol metabolites do exhibit levels of antioxidant activity, yet it is lower than the 
parent compound because their radical scavenging  OH groups may be blocked by 
sulphation, glucuronidation, or methylation (Halliwell 2007). In a study investigating the 
chemoprotective activity of sulfate metabolites of resveratrol, two were able to inhibit 
COX activity and NO production (Hoshino et al. 2010). It has also been demonstrated 
that resveratrol metabolite, resveratrol--O-sulfate inhibits COX-1 and COX-2 activity, 
which help to exert cardioprotective and anticancer effects. Other sulfate metabolites, 
have been suggested to promote longevity through inhibition of SIRT1 (Calamini et al. 
2010). Resveratrol-3-O-sulfate was able to inhibit colon cancer cell proliferation having 
the potential to act as a chemotherapeutic drug to induce apoptosis (Aires et al. 2013). 
Interestingly, a mixture of metabolites, resveratrol-3-O-sulfate, resveratrol-3-O-D-
glucuronide and resveratrol--O-D-glucuronide, induced anti-proliferative activity 
greater than resveratrol (Aires et al. 2013). It has also been reported that the sulfate 
conjugates have anti-inflammation properties (Hoshino et al. 2010; Lasa et al. 2012a). 
Piceatannol (3, 3  -trans-trihydroxy stilbene) another resveratrol metabolite, has also 
shown potential to have activity in activation of AMPK and GLUT4 translocation, 
suggesting prevention and improvement for diseases such as type 2 diabetes (Minakawa 
et al. 2012). Also it has been studied for its antioxidant, anti-cancer, and apoptotic effects 
(Piotrowska et al. 2012). Accordingly, resveratrol metabolites are involved in diverse 
biochemical processes that have the potential to exert positive health promoting effects; 
yet their action is dependent on the specific function investigated.  
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1.10.1 Resveratrol metabolites in lipid metabolism 
 Currently, there is minimal knowledge of the effect of resveratrol metabolites in 
adipose tissue and lipid metabolism. One study demonstrated several resveratrol 
metabolites had a significant reduction of TAG levels in maturing pre-adipocytes and 
mature adipocytes (Lasa et al. 2012a). Resveratrol- -O-glucuronide and resveratrol 3-O-
sulfate both showed significant reductions in lipid species in maturing pre-adipocytes 
greater than resveratrol. Resveratrol-3-O-glucuronide and resveratrol- -O-glucuronide 
both showed delipidating effects in mature adipocytes. Taken together, resveratrol 
metabolites, target both maturing pre-adipocytes as well as mature adipocytes and may 
been involved in anti-obesity effects (Lasa et al. 2012a) 
In studies identifying the tissue distribution and levels of resveratrol metabolites, 
have noted that not all the metabolites have been identified (Cottart et al. 2010). There is 
large inter-individual variability in metabolism and the fate of up to 30% of resveratrol 
dosage may not be recovered in urine or feces. Due to the various distribution of 
resveratrol and its metabolites, there may be other metabolites which have been bound to 
cellular membranes of lipophilic fractions and tissue and gone undetected (Cottart et al. 
2010). Therefore other resveratrol metabolites, such as trans-   -trimethoxy 








bioavailability and rapid metabolism, and be a an alternative source for increasing health 




 -trimethoxy resveratrol 
Stilbenes are widely available in foods such as mulberries, grapes, red wine, and 
peanuts (Shi et al. 2012). Food and herbs which contain beneficial phytochemicals have 
potential at curbing the increase of metabolic disorders and diseases. Although studies 
have supported the use of resveratrol in prevention of diseases, stilbenes related to 
resveratrol with the same backbone but differing substituents may contain greater 
potency (Dias et al. 2013). In an attempt to understand the role of resveratrol analogs that 





trimethoxystilbene or trans-   -trimethoxy resveratrol (TMR). It is naturally found in 
the Pterobolium hexapetallum plant (Aggarwal et al. 2004) and has also be isolated from 
Virola cuspidata (Blair et al. 1969). The methoxy groups attached to TMR enhances the 
transportation to cells as well as metabolic stability; it is partially protected from further 
metabolism by enzymatic glucuronidation or sulfation. Also, TMR has greater 
lipophilicity and is highly likely to be distributed into fat tissues, and generally found in 
larger amounts in major organs than plasma (Dias et al. 2013). In a pharmacokinetic 
study, TMR maintains enhanced properties in clearance, plasma exposure, as well as 
absolute bioavailability (Lin et al. 2009).  
 
1.11.1 Anti-cancer activity 
Dietary factors that have the ability to modify progression and carcinogenesis are 
of large interest in epidemiological studies. Several studies have identified TMR as a 
potential anti-cancer agent, acting in vitro and in vivo, for its chemoprotective properties 
in various cancer types which include colon, leukemia, breast, and prostate. TMR has 
been shown to be different that other stilbenes in regards to its mechanism of cytotoxicity 
on neoplastic cells; suggesting its efficacy in different cancers (Simoni et al. 2006). TMR 
observed in HL60 cells, was highly active due to its structure-function activity 
relationship. The methoxy derivatives from resveratrol showed significantly better 
activity against HL60 leukemic cells (Simoni et al. 2006). Also noted, was that in many 
studies, stilbenes act as phase-specific drugs, blocking cells in a specific phases of the 
cell cycle. For example, resveratrol and piceatannol induced a block in the S phase, 
suggesting that they act as phase-specific cytotoxic agents. However, TMR demonstrated 
no modification in cell cycle distribution (G0-G1, S, or G2-M) compared to the control. 
Overall, TMR maintained cytotoxic and apoptotic-induced activity and an ability to 
reduce neoplastic cells in all phases of the cell cycle (Simoni et al. 2006). TMR also was 
more potent than resveratrol against different human cancer cells lines including HT-29 
(human colon adenocarcinoma), PC-3 (human prostate cancer), and COLO25 (human 
colorectal carcinoma) (Pan et al. 2008). The presence and location of the methoxy groups 
can be attributed for the biological activity, seen within hours of treatment. The induction 
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of apoptosis with TMR treatment is credited to its strong inhibition of cell viability, 
causing potent apoptosis and DNA laddering in COLO25 cells (Pan et al. 2008). TMR is 
thought to trigger apoptosis via p53 dependent proteins and effecting mitochondrial 
function. In vivo, TMR significantly reduced tumor growth in SCID mice with no 
cytotoxic effects in the mice when dosed at 50 mg/kg (Pan et al. 2008). Taken together, 
TMR may have potential in inhibiting cancer proliferation in colorectal carcinomas.  
Similarly, in human prostate cells, TMR showed limited DNA damage, which 
could trigger reduced stimulation of p53 and subsequently p21 (Hsieh et al. 2011a). TMR 
maintained little effect on the cell cycle transition in CWR22Rv1 cells, but did decrease 
G1 and expanded G2M in PC-3 cells, different from other resveratrol metabolites. This 
suggests that TMR is active against different stages in prostate cancer cells and may use 
distinct mechanisms (Hsieh et al. 2011a). TMR studies in cell proliferation assays in 
three types of cells, LNcaP, Du145, and PC3M, demonstrated higher potency in growth 
inhibition than resveratrol with highest potency in LNCaP cells (Dias et al. 2013). Also, 
TMR dose-dependently inhibited colony formation in LNCaP-Luc cells in vivo with large 
reductions in size and number of colonies (Dias et al. 2013). Finally, to elucidate the anti-
cancer effects in vivo using xenografts with prostate cancer cells, TMR pretreatment in 
mice helped to attenuate tumor development and progression. It was proposed that the 
phytochemicals created a microenvironment in which tumor initiation and development 
was reduced. Reported data shows TMR had enhanced anti-proliferative, anti-clonogenic, 
and anti-inflammatory properties, also higher amounts of TMR located in serum and 
target tumor tissue compared with resveratrol (Dias et al. 2013). With in vitro studies 
with breast cancer cell lines, TMR was able to induce apoptosis. And in biochemical 
analysis it is suggested that upon    	
 	    
pathway is stimulated leading to p53 activation and apoptosis which is different than 
routes seen with resveratrol and piceatannol (Hsieh et al. 2011b).  
 
1.11.2 Antiangiogenic activity 
Uncontrolled endothelial cell proliferation is commonly seen in tumor 
neovascularization and angioproliferative diseases. Two models to affect 
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neovascularization include identification of antiangiogenic compounds which prevent 
new blood vessel development, and disruption by vascular-targeting agents within 
neovasculature (Belleri et al. 2005). TMR has demonstrated efficacy in both areas and is 
identified as a microtubule-destabilizing agent, causing rapid, microtubule 
depolymerization in endothelial cells. Results indicated that TMR has antiangiogenic and 
vascular-targeting capacity and inhibits tumor proliferation (Belleri et al. 2005).  
TMR evaluated for its cytotoxicity in human cancer lines was studied in human 
endothelial cells and zebra fish blood-vessel formation in vivo (Alex et al. 2010). TMR 
demonstrated its high potency as an antiangiogenic and vascular disrupting agent, greater 
than resveratrol in vitro and in vivo. TMR showed different efficacy in three cancer cells 
lines (HepG2 (human hepatoma), and human breast adenocarcinoma (MCF-7 and MDA-
MB-231)) in vitro, compared to resveratrol. And in HUVECs (human umbilical vein 
endothelial cells) in vitro and zebra fish embryo in vivo,   	
	
	 		
was more potent and expressed greater specific cytotoxic effects on endothelial cells. 
Mechanistically, further insight showed TMR may act through down regulation VEGFR2 
expression in the VEGF/VEGR pathway and cause cell-arrest at G2/M phase (Alex et al. 
2010).  
 


















































 -hexosaminidase by ionomycin in 
RBL-2H3 cells, which correlates to anti-allergenic activity (Matsuda et al. 2004). In 
murine hippocampal HT22 cells, TMR failed to protect the cells from glutamine-induced 
cytotoxicity and was unable to increase HO-1 expression and SIRT1 activation. HO-1 has 
been reported as one of the main mediator of antioxidant activity and cytoprotection 
(Kim et al. 2012). Therefore increased expression HO-1 is partially responsible for 
cytoprotective actions in HT22 cells. The data suggests that the methoxy groups of TMR 
interfere with its ability to resist oxidative stress (Kim et al. 2012).  
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Overall, TMR presents as a biologically active resveratrol metabolite and analog 
in variety of cellular functions and in different cells types. However, its specific role in 
  	
      
 	 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 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 systems 
reveals its activity and suggests it may have potential in a wide range of areas for 
beneficial health effects.  
 
1.12 In vitro model 
In vitro systems used to study adipocyte function have been used for the last 30 
years and helped to identify molecular mechanisms and distinct cellular events (Gregoire 
et al. 1998). Cell lines which are morphologically similar to primary preadipocytes in a 
fibroblast like shape, and are able to transform into round, lipid accumulating mature fat 
cells have been established. Preadipose cell lines have already committed to adipocyte 
lineage and are able to represent different stages of adipocyte differentiation (Cornelius et 
al. 1994; Gregoire et al. 1998). One of most frequently used and studied cell lines 
includes 3T3-L1 cells. They are beneficial in studying molecular events in adipocyte 
biology because they are well characterized, a reliable model, and can be passaged 
indefinitely allowing for a consistent source for investigation (Ntambi and Kim 2000). 
Additionally, since these cells are derived from cloning their homogeneity helps to yield 
conclusive results to different treatments. 3T3-L1 cells were initially selected as a 
consistent model for preadipocyte differentiation because of their ability to accumulate 
TAG (Cornelius et al. 1994). When injected into mice, 3T3-L1 preadipocytes not only 
differentiated and formed fat pads, they were histologically indistinguishable from the 
normal adipose tissue (Cornelius et al. 1994; Ntambi and Kim 2000). In cell culture 
protocols, 3T3-L1 rapidly and in sync can proliferate and differentiate with very similar 
characteristics of adipocytes from animal tissue; formation of LD are also very similar to 
those seen in vivo adipose mass (Ntambi and Kim 2000). These cells are also very 
coordinated to the pathways of de novo FA and TAG biogenesis demonstrated through 
expression of every enzyme involved (Macdougald and Lane 1995).  
Nonetheless, there are some disadvantages to using cell lines in studying 
adipocyte biology. Being that these cells are aneupolid, they may not always accurately 
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resemble preadipocytes found in vivo  along with the fact that they are out of the context 
of a normal extracellular matrix (Ntambi and Kim 2000; Rosen et al. 2000). And while 
these types of cell lines have similar characteristics, across the board there may be 
differences between the established lines. Presumably, these differences are due to the 
stage of preadipocyte differentiation that the cloning occurred (Macdougald and Lane 
1995). Preadipocytes in these cell lines represent early, intermediate, or late stage 
development, therefore the response to different hormones or treatments may be varied 
(Macdougald and Lane 1995; Ntambi and Kim 2000). Most all cell lines differentiate into 
WAT exclusively, and do not represent any changes to BAT. Finally, preadipose cells 
lines may not be derived from the same fat depot, which is an important consideration 
because there are known differences in metabolic behavior of mature adipocytes between 
visceral and subcutaneous fat pads (Rosen et al. 2000). However, almost all work in 
investigating adipogenesis and other adipocyte functions have used clonal cells lines, 
stemming from the stromal vascular fraction. Overall, established preadipose cells lines 
used in vitro represent a useful tool in preliminary understanding of in vivo systems.  
 
1.13 Conclusions and research objectives 
Metabolic syndrome is associated with a variety of health risk factors including 
abdominal obesity, blood lipid disorders, inflammation, insulin insensitivity, type 2 
diabetes, and elevated risk of cardiovascular disease (Despres and Lemieux 2006). In an 
obesogenic condition, dysfunctional adipose tissue is unable to appropriately store excess 
energy and increased basal lipolysis occurs; leading to increased levels of circulating 
NEFA which can have severe metabolic consequences (Duncan et al. 2007). A surplus of 
NEFA results in uptake in non-adipose tissue and ectopic fat deposition which can induce 
other conditions including dyslipidemia, hyperglycemia, inflammation, and insulin 
resistance (Despres and Lemieux 2006). Studies identifying novel ways to alleviate 
adipose lipolysis and NEFA release may provide approaches to treat obesity-induced type 
2 diabetes and other metabolic syndromes. Identification of dietary components as a 
strategy to combat obesity and its associated disorders may be via phytochemicals. 
Currently, there is a knowledge gap in investigation the regulation of adipose tissue 
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lipolysis by dietary components. To date, there is no clear evidence of adipose lipolysis 
modulation by dietary components, expect one report recognizing resveratrol action on 
the stimulation of lipolysis (Lasa et al. 2012b). Our lab has previously demonstrated that 
piceatannol, a resveratrol metabolite, has antilipolytic activity in vitro and in vivo (Kwon, 
unpublished). However, little is known about resveratrol metabolites, specifically, TMR, 
in lipid metabolism and its affect in specific adipose functions. Thus, the work in this 
thesis has been completed with the following objective, aims, and hypothesis.  
 
Our overall working hypothesis is that resveratrol metabolites affect lipid metabolism by 
modulating the lipolysis process.  
 
Objective: Identify and determine the effect of different resveratrol metabolites and their 
role in adipose function 
Aim 1: Determine the effect of resveratrol metabolites on lipolysis in adipocytes in vitro 












Figure 1.1 Cascade of 3T3-L1 preadipocyte differentiation and adipogenic program 
in vitro. With the appropriate environment and gene expression induction, preadipocytes 
undergo mitotic clonal expansion which is then followed by terminal differentiation. The 
conversion is a result of up- and down-regulation of specific transcription factors and 
genes. The process of differentiation takes place over the course of 6 days, beginning 
with a fibroblast-like preadipocyte until full maturation of a round lipid-containing 







Figure 1.2 Lipolytic cascade in adipocytes. ATGL binds to CGI-58 and facilitates 
lipolysis via hydrolysis of TAG to DAG and NEFA. With signal transduction from 
  	
 	 -adrenergic receptors (-AR) and G protein-mediated signaling (Gs), 
activates adenylyl cyclase(AC), resulting in increased levels of cAMP, activating PKA, 
which phosphorylates HSL and perilipin A. Conformational changes occur in perilipin A, 
and pHSL translocates to the surface of the LD and hydrolyzes DAG to MAG and NEFA. 
Cytosolic MAG hydrolyzes MAG into NEFA and a glycerol backbone. NEFA and 
glycerol are released into circulation. Adapted from Lafontan and Brasaemle (Brasaemle 








Figure 1.3 Metabolic syndromes with ectopic fat distribution. Excess visceral fat 
accumulation is associated with insulin resistance and also a marker of dysfunctional 
adipose tissue due to inability for the body to appropriately store surplus energy. In 
metabolic dysfunction, with high levels of circulating NEFA, fat deposition is stored in 
undesirable locations including the liver, heart and muscle. Metabolic syndrome ensures 
with this condition as well as other metabolic consequences including visceral obesity, 
insulin resistance, dyslipidemia, and inflammation, which could result in increased risk of 






Figure 1.4 Structure of resveratrol and resveratrol metabolites. (A) Resveratrol, (B) 
Piceatannol, (C) Resveratrol- -O-glucuronide, (D) Resveratrol-3-O-glucuronide, (E) 
Trans-
 




CHAPTER 2.  MATERIALS AND METHODS 
2.1 Introduction 
To test our overall goal and achieve our specific aims we used a variety of 
techniques to elucidate the effects of resveratrol metabolites. We utilized an in vitro 
model by means of 3T3-L1 cells as an established cell line. The cells were passaged as 
preadipocytes and differentiated into mature adipocytes and incubated in the presence of 
different resveratrol metabolite treatments to understand their role in lipolysis. Upon 
further investigation, preadipocyte cells were differentiated in the presence or absence of 
trans-   -trimethoxyresveratrol (TMR) to gain understanding its role in lipogenesis. 
We utilized both qualitative and quantitative techniques to investigate our findings. 
Additionally, biochemical and molecular tools were used to gain knowledge into specific 
mechanisms of action. The following accounts for the materials and methods used during 
our research processes.  
 
2.2 Materials and methods 
 
2.2.1 Materials and reagents 
Trans-   -trismethoxy resveratrol (TMR) was provided by Cayman Chemical 
(Ann Arbor, MI). Trans-resveratrol-3-O--D-glucuronide (3G) and trans-resveratrol--
O--D-glucuronide (4G) were obtained from Toronto Research Chemicals (North York, 
ON, Canada). Piceatannol (PIC) was purchased from Alexis Biochemicals (Lausen, 
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Thermo Scientific (Waltham, MA). Penicillin-streptomycin, sodium pyruvate, and 0.25% 




3-isobutyl-1-methylxanthine (IBMX), insulin, free glycerol reagent and RNase Away 
were purchased from Sigma-Aldrich (St. Louis, MO). Fetal calf serum (FCS) and fetal 
bovine serum (FBS) were obtained from PAA (Darthmouth, MA). TRIzol® reagent as 
well as SuperScriptII was bought from Invitrogen. Protein assay kit was from Bio-Rad 
laboratories (Hercules, CA). 3-(4.5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium 
bromide (MTT) was purchased from Alfa Aesar (Ward Hill, MA). Antibodies against 
  -actin, and secondary mouse antibodies were from Santa Cruz Biotechnology 
(Santa Cruz, MA). Phospho-HSL (ser660) and secondary rabbit antibodies were obtained 
from Cell Signaling Biotechnology (Beverly, MA). CGI-58 was used from BioVision 
(Milpitas, CA). Acetonitrile, methanol, water (Mallinckrodt-Baker, Phillipsburg NJ), and 
formic acid (Sigma-Aldrich St. Louis, MO) used in sample preparation and analysis were 
certified HPLC-MS and ACS grade.  
 
2.2.2 3T3-L1 cell culture 
3T3-L1 preadipocytes were sourced from American Type Culture Collection and 
were cultured in 10% (v/v) FCS-DMEM in a humidified environment with 5% CO2 at 
37oC. Cells were designated known passages and were not cultured past passage nine. 
Preadipocytes had new FCS-DMEM changes every two days until growth had reached 
approximately 80% confluence, at which point cells were split and expanded into 100mm, 
60mm, 6-, 12-, or 24-well plates for further proliferation until differentiation. 
Preadipocytes were kept in a sub-confluent state until induced to differentiate after two 
days of post-confluence (entitled Day 0), with standard adipogenic cocktail (DMI) 
comprising of 1 µg/ml insulin, 5 µg/ml DEX, and 0.5 mM IBMX in 10% FBS-DMEM 
for two days. After two days of incubation, 10% FBS-DMEM medium including only 
insulin was added to the maturing adipocytes and at day four to solely 10% FBS-DMEM, 
and was changed every two days until adipocytes are fully differentiated to mature cells 
(day 8-10) when lipid droplets are clearly visible. Cells which had differentiated with 
greater than 90% into mature adipocytes were used for experiments. All media consisted 




2.2.3 Treatment condition 
Purchased metabolites (TMR, 3G, 4G, and PIC) were each dissolved in dimethyl 
sulfoxide (DMSO) as recommended by the supplier. Stock solutions were diluted to 50 or 
100 mM and aliquots were generated to keep freeze-thaw cycles to a minimum, with a 
maximum thaw number of three times. For treatment of cells, stock solutions were 
diluted into DMEM media to a final working concentration and applied to cells. 
Preadipocytes were induced to differentiate with the adipogenic cocktail and in the 
presence or absence of a specific treatment and continued to receive treatment every two 
days until day 6.  Mature adipocytes at day 8 to day 10 after differentiation were treated 
in serum free medium for a set period of time with the designated treatment conditional 
to the experimental design.  
 
2.2.4 Oil Red O (ORO) staining 
ORO staining was done on day six to visualize and quantify intercellular lipid 
droplet accumulation (Koopman et al. 2001). 3T3-L1 cells were subjected to oil red O 
lipid soluble dye as described with protocol adjustments (Ramirezzacarias et al. 1992). 
Briefly, medium was removed from cells in each well and washed twice with phosphate 
buffered saline (PBS). Cells were then subjected to 3.7% formaldehyde for 0.5-1 hour at 
room temperature or overnight at 4oC to fix the cells. Plates were then washed with 
double distilled water twice and a filtered working solution of ORO was applied to fixed 
cells and incubated at room temperature for greater than 30 minutes. Cells were then 
rinsed with distilled water by submersion and dried. Scanned images were taken of ORO-
stained cells. Quantification of ORO-stained lipid droplets was done with isopropyl 
alcohol extraction and absorbance measured spectrophotometrically at 490 nm with a 
microplate reader (Bio-Rad). The quantification was calculated based on the ORO stain 
as a percent of the control.  
 
2.2.5 Cell viability assay 
A 3-(4.5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) reduction 
was utilized in order to determine the effect of different concentrations of trans-   -
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trismethoxy resveratrol (TMR) on cell viability. This assay allows for the quantification 
of active mitochondrial function based on their ability to reduce the yellow MTT solution 
in the presence of dehydrogenase enzymes into a purple formazan product (Gerlier and 
Thomasset 1986). Both proliferating preadipocytes and mature adipocytes were incubated 
with different concentrations of TMR for 24 hours in serum free DMEM. The cells were 
then incubated with the MTT assay solution (0.5 mg/ml) for one hour at 37oC in 5% CO2. 
Upon development of the violet precipitate, the contents were then dissolved in DMSO 
and quantified by absorbance measured spectrophotometrically with a microplate reader 
(Bio Rad) at a wavelength of 595 nm. The amount of formazan, calculated as a percent of 
control, is representative of final cell viability.  
 
2.2.6 Lipolysis assay 
The measure of free glycerol in media samples is representative to the amount of 
lipolysis that occurs in samples based on hydrolysis of triglycerides into free fatty acids 
and a glycerol backbone. This method was used to determine the level of lipolysis in both 
basal and stimulated conditions of fully differentiated cells. The free glycerol reagent 
measures free glycerol by using the same coupled enzymes reactions and produces a 
quinoneimine dye, observed as a purple hue. Serum free DMEM with 10 µM 
isoproterenol and 0.5 mM IBMX (stimulated) or without (basal) added was added to 
mature adipocytes in the presence or absence of the different resveratrol metabolite 
treatments at different concentrations. After incubation periods, aliquots of the medium 
were collected and analyzed for free glycerol. Samples of the media were gently mixed 
with the free glycerol reagent and incubated at 37oC for 5 minutes according to supplier 
protocol. Quantification of the product was measured spectrophotometrically at minimum 
absorbance of 540 nm using a microplate reader (Bio Rad). The increase in absorbance is 
directly proportional to the free glycerol concentration in the sample. Glycerol release 




2.2.7 Immunoblot assay 
Western blot analysis was employed to measure the amount of protein expressed 
by cells treated with different experimental groups as described (Burnette 1981) with 
modifications. The cells were cultured and treated as specified in each experiment and 
collected by scrapping in phosphate buffer saline (PBS). Samples were immediately 
centrifuged to remove excess PBS. Cell pellets were then transferred to lysis buffer 
comprising of Tris-HCl (100mM (pH 8.0)), NaCl (100mM), 0.5% Triton X-100, protease 
inhibitor blend, sodium fluoride (10mM) and sodium orthovanadate (1mM). The 
concentration of protein was quantified with the Bradford method (Bio-Rad Laboratories, 
Hercules, CA). 100 µg of protein sample were separated with a 10% sodium dodecyl 
sulfate-polyacrylamide gel (SDS-PAGE) and transmitted to a nitrocellulose membrane. A 
protein ladder, Precision Plus Protein Standards Kaleidoscope (Bio-Rad) was employed 
to identify protein size (kDa). Membranes were blocked in 5% non-fat dry milk in 1% 
Tween-Tris Buffered Saline (TTBS) for two hours at room temperature. Immunoblotting 
was completed with respective primary antibodies at 4oC overnight, followed by washing 
in 1% TTBS (3 times for 5 minutes). Signals were seen with horseradish peroxidase-
conjugated secondary antibodies (Santa Cruz Biotechnology) which were incubated for 
two hours at room temperature, followed by washing (3 times for 6 minutes) and 
enhanced with Pierce enhanced chemiluminescence plus Western Blotting reagents with 
autoradiography. Film was scanned and protein band intensity was quantified with NIH 
  	
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stripped with a mild stripping buffer (0.2 M glycine, 0.1% SDS, 1% Tween20, pH 2.2 1 L 
dd water) at room temperature, and re-blocked. 
 
2.2.8 Total RNA isolation and real time reverse transcription polymerase chain reaction 
(RT-PCR) 





fl  ocyte cells were treated for 
duration of time depending on experimental design or during differentiation at various 
concentrations of TMR. Media was aspirated and cells were washed with PBS. TRIzol ® 
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was added to the cells, harvested, and stored at -80oC until subjected to RNA isolation. 
The integrity of the isolated RNA was determined with NanoDrop 2000c 
(ThermoScientific) using the 260nm/280nm ration. Samples that maintained a ratio 
greater than 1.8 were used. 1µg/µl of isolated RNA was subjected to the reverse 
transcriptase reaction utilizing SuperScriptII system, and cDNA was synthesized. Newly 
synthesized cDNA was used for real time reverse transcription PCR reactions using 
Applied Biosystems Step One real time PCR thermocycler. The cDNA was diluted and 
amplified using a SYBR premixed Taq reaction mixture with PCR primers. Reactions 
were performed in triplicate for each pair of 100 n/ml PCR primers with values 
 	
  			  	 	 -actin, expression. The forward and reverse primer 
sequences used in the study are shown in Table 2.1. Analysis of RT-PCR data was 
		
   T scheme and calculated as relative changes in gene expression.  
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Table 2.1. Primer sequences corresponding to genes used in quantitative RT-PCR 
(F) represents nucleotide sequence for the forward primer and (R) represents nucleotide 
sequence for the reverse primer.  
Gene (F) 5'- 3' sequence (R) 5'- 3' sequence 
PPA  CCC AAT GGT TGC TGA TTA CAA T CTA CTT TGA TCG CAC TTT GGT ATT CT 
FAS GCC ACC CAC CGT CAG AAG TGT CAC ATC AGC CAC TTG AGT GT 
ACC GAA TCT CCT GGT GAC AAT GCT TAT T GGT CTT GCT GAG TTG GGT TAG CT 
SCD1 GGT GAT GTT CCA GAG GAG GTA CTA C AGC GTG GGC AGG ATG AAG 
MGAT1 CTG GTT CTG TTT CCC GTT GT TGG GTC AAG GCC ATC TTA AC 
DGAT2 GCC GTG TGG CGC TAC TTC GTG GTC AGC AGG TTG TGT GTC T 
SREBP1c GGC ACT GAA GCA AAG CTG AAT GGC ACT GAA GCA AAG CTG AAT 
Resistin TGC CAG TGT GCA AGG ATA GAC T CGC TCA CTT CCC CGA CAT 
Leptin CAC ACA CGC AGT CGG TAT CC AGC CCA GGA ATG AAG TCC AA  
Adiponectin GAT GCA GGT CTT CTT GGT CCT AA GGC CCT TCA GCT CCT GTC A 
Adipsin GCT ATC CCA GAA TGC CTC GTT TTC CAC TTC TTT GTC CTC GTA TTG 
UCP1 GCC AAA GTC CGC  CTT CAG AT TGA TTT GCC TCT GAA TGC CC 
PGC- CCC AGG CAG TAG ATC CTC TTC AA CCT TTC GTG CTC ATA GGC TTC ATA 
Tfam TCC TGA GGA AAA GCA GGC ATA T CAT TTC ATT GTC GTA ACG AAT CCT A 
NRF1 GCC GTC GGA GCA CTT ACT G GGC CAT GAT TTC TGG AAG CA- 
NRF2 TCC CAGGTT GCC CAC ATT TGC CAA AAG CTG CAT ACA GTC T 
MCAD CAA CAC TCG AAA GCG GCT CA ACTTGCGGGCAGTTGCTTG 
CPT1 GCT GCT TCC CCT CAC AAG TTC C GCT TTG GCT GCC TGT GTC AGT ATG C 
Tbx1 GGC AGG CAG ACG AAT GTT C TTG TCA TCT ACG GGC ACA AAG 
Tmem26 ACC CTG TCA TCC CAC AGA G TGT TTG GTG GAG TCC TAA GGT 
Prdm16 CAG CAC GGT GAA GCC ATT C GCG TGC ATC CGC TTG TG  
ATGL GAG ACC AAG TGG AAC ATC GTA GAT GTG AGT GGC GTT 
CGI-58 GGT TAA GTC TAG TGC AGC AAG CTG TCT CAC CAC 
HSL TGT GGC ACA GAC CTC TAA AT GGCATATCCGCTCTC 
Perilipin TGC TGG ATG GAG ACC TC ACC GGC TCC ATG CTC CA 




2.2.9 Stimulated Raman scattering (SRS) and two-photon excitation fluorescence (TPEF) 
imaging 
Stimulated Raman scattering (SRS) imaging was performed on a femto-second 
laser (InSight DeepSee, Spectra-Physics, Mountain View, CA) system, as described 
previously (Wang et al. 2013; Zhang et al. 2011). Mature adipocytes were treated for 
three hours with 50µM TMR and subjected to both SRS and TPEF imaging. Briefly, with 
the stokes beam fixed at 1040 nm, the pump beam is tuned to 800 nm to match the CH2 
stretch vibration at 2850 cm-1. A water immersion objective lens (60X, UPlanSApo, 
Olympus, Tokyo, Japan) with numerical aperture of 1.2 was used to focus the light on the 
sample. The average power used is 30 mW for the pump beam and 75 mW for the stokes 
beam. For Two-Photon Excited Fluorescence (TPEF) imaging of intracellular TMR 
compound, the pump beam at 800 nm was used as the excitation source. Forward signal 
was detected by a PMT (H7422-40, Hamamatsu) after a 410/40 nm bandpass filter. The 
imaging acquisition time is 10 µs per pixel. Images were analyzed using Image J software.  
 
2.2.10 High performance liquid chromatography (HPLC) with ultraviolet (UV) detection 
In order to determine the effect of TMR stability in media an HPLC system with 
UV-VIS detector was used as previously described (Lin and Ho 2009; Lin et al. 2010) 
with modifications. Briefly, TMR at 50 µM added to serum free medium incubated at 
37 C were collected at 0, 3, 6, 9 and 24 hours and stored at -80  C.  Samples with 2% 
formic acid in acetonitrile were vortexed and centrifuged at 14,000 x g for 5 minutes to 
precipitate any proteins in the sample. Finally the supernatants were filtered through a 
  	
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equipped and a Waters 2996 Photodiode Array Detector. Separation was achieved with a 
RPC18column (XBridge BEH Shield RP18 2.5 µm, 2.1 x 100mm) through delivery of a 
mobile phase of 95% acetonitrile-water (75:25, v/v) containing 5% and  0.1% formic acid 
respectively at a flow rate of 0.25 ml/min with a run time of 10 minutes. TMR was 
detected at a wavelength of 300 nm and quantified using calibration curves constructed 





2.2.11 Statistical analysis 
Data are displayed as means ± SEM. Statistical analysis was performed using 
SAS 9.3 software. One-way analysis of variance was used to determine significance of 
treatment interactions and effect. Statistical significant comparisons between each group 
   	
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performed in duplicate or triplicate, with representative images. P values lower than 0.05 
were regarded as statistically significant.  
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CHAPTER 3. RESULTS AND DISCUSSION 
3.1 Introduction 
The prevalence and growth of obesity has drastically increased and expanded into a 
global health issue (Kim et al. 2013). Currently two thirds of the population in the United 
States are overweight, with a third being considered obese (Ogden et al. 2014). 
Consequently, obesity is highly associated with other metabolic diseases including 
insulin resistance and type 2 diabetes, cardiovascular diseases, and certain cancers 
(Despres and Lemieux 2006). Adipose tissue plays a critical role in whole body energy 
homeostasis and lipid metabolism. Adipocyte development is a result of hypertrophy, an 
increase in cell size, as well as hyperplasia, an increase in cell number (Kim et al. 2013). 
Hypertrophy occurs in mature adipocytes and this process is critical for lipid storage and 
secretion of hormones which maintain overall energy balance. Hyperplasia is responsible 
for generation of new adipocytes primarily seen in adolescence and adult adipocyte 
turnover (Kim et al. 2013). Both processes are targets for the prevention and or treatment 
of obesity in therapeutic strategies.  
 Obesity is associated with metabolic diseases that include type 2 diabetes. 
Currently, NEFA at amplified levels have suggested as a mediator linking the two 
conditions (Despres and Lemieux 2006). Lipolysis is the process in adipose tissue 
responsible for the mobilization of these NEFA into circulation and it commonly seen at 
an increased level in obese patients, which can be precursor to other detrimental 
metabolic syndromes (Duncan et al. 2007). Therefore, studies investigating strategies to 
attenuate lipolysis and subsequent NEFA release may be an approach to treating obesity-
induced type 2 diabetes. Currently, there is limited knowledge in regards to examining 




previously shown a resveratrol metabolite, piceatannol, has antilipolytic activity (Kwon, 
unpublished). Thus, we hypothesized that other resveratrol metabolites may also have an 
effect in in modulating lipid metabolism and play a role in reducing adipose lipolysis. 
Furthermore, the objective of this study is to identify and determine the effect of different 
resveratrol metabolites and their role in adipose function. Using cellular and biochemical 
techniques, we examined the role of the resveratrol metabolite, TMR, in lipid metabolism, 
with a focus on lipolysis and lipogenesis.  
 
3.2 Adipose function: Lipolysis 
WAT are fat stores and major energy reserves in mammals. With food intake, 
NEFA are esterified to a glycerol backbone and stored as neutral lipids in the form of 
TAGs and deposited in LD (Lass et al. 2011). During fasting or increased energy 
expenditure, TAGs are mobilized and FA are sequentially cleaved by lipases, released, 
and circulated to peripheral tissues to undergo  -oxidation and generate ATP (Lass et al. 
2011). This mobilization and hydrolysis of FA from the glycerol backbone is known as 
lipolysis (Zechner et al. 2012). Adipocyte lipolysis occurs sequentially and is a highly 
regulated process in that each step is carried out by a different lipolytic enzymes (Walther 
and Farese 2012). The first FA cleaved from TAG is done by ATGL, the second is 
removed by HSL, and the third by MGL resulting in three NEFA and a glycerol 
backbone (Ahmadian et al. 2009).  
 NEFA plasma concentrations are increased in obesogenic conditions and are a 
common cause for the dysregulation of lipolysis (Lafontan and Langin 2009). Currently, 
there is evidence that shows impaired NEFA metabolism is a contributing factor for 
insulin resistance in visceral obesity (Despres and Lemieux 2006). Increased circulating 
NEFA pose a serious issue in that with excess fat accumulation and dysfunctional 
metabolic state, ectopic fat disposition occurs where excess energy is stored in 
undesirable locations including the heart, liver, and muscle (Despres and Lemieux 2006). 
Additionally, NEFA at increased levels are thought to be a mediator linking obesity and 
type 2 diabetes through  -cell dysfunction, and as previously mentioned, insulin 
resistance (Kahn et al. 2006). Therefore, it has been proposed that identifying 
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antilipolytic agents to partially inhibit lipolysis may help to attenuate the level of 
circulating NEFA, and the development of dyslipidemia and metabolic syndromes 
(Langin 2006a).  
 
3.2.1 Impact of resveratrol metabolites on lipolysis in 3T3-L1 adipocytes 
As reviewed in the literature, resveratrol metabolites have varying function and 
effects in different types of cells and their role is dependent on the function being 
analyzed. To better understand the effects of different resveratrol metabolites, specifically 
in lipolysis, several metabolites were tested on mature 3T3-L1 cells which had greater 
than 90% lipid accumulation. 3T3-L1 cells were treated with resveratrol metabolites 
inc  	

     -trans-tetrahydroxystilbene) (PIC), trans-  -
trimethoxy resveratrol (TMR), resveratrol-3-O-glucuronide (3G), resveratrol--O-
glucuronide (4G) compared to the control vehicle, DMSO. Mature adipocytes were 
incubated with serum free medium and treated in both the basal and stimulated conditions. 
Incubating mature adipocytes in these two different conditions are necessary to mimic 
two different physiological conditions. The basal condition imitates a resting metabolic 
state in a neutrally temperate environment, or in other words, the energy that is expended 
by humans at rest, in a post-absorptive state sufficient for only functioning organs. A 
stimulated condition mimics a fasting condition such as after an acute exercise state 
where lipolysis is induced. In this cellular model, 3T3-L1 cells were treated in both 
conditions and stimulated by addition of isoproterenol (ISP) or forskolin (FSK). FSK 
works to stimulate and increase accumulation of cAMP in intact cellular systems 
(Seamon et al. 1981), and ISP is a -adrenergic agonist that stimulates -adrenergic 
receptors and increases levels of cAMP and AMPK to promote the lipolytic pathway 
(Fasshauer et al. 2002a; Minokoshi et al. 2002). Quantification of glycerol release, 
normalized by protein, allowed us to see the effect of metabolite action on lipolysis. Each 
metabolite was screened at a concentration of 50 µM; this is an intermediate range used 
in treatment of phytochemicals (Minakawa et al. 2012) and a level that has been 
previously used in our lab. Additionally, 50 µM is a frequently used with in vitro studies, 
including those examining the effects of resveratrol (RES) on 3T3-L1 adipocytes (Park et 
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al. 2008; Rayalam et al. 2008b). From an acute 1.5 hour treatment, PIC, TMR, and 3G 
show a significant reduction in lipolysis in the basal condition compared to the control 
(Figure 3.1 A). The significant inhibition of PIC on lipolysis has been demonstrated in 
our lab both in vitro and in vivo (Kwon, unpublished) and is confirmed in these data. Our 
new finding of the partial, significant inhibition of lipolysis by TMR and 3G in an acute, 
basal treatment has not been reported. The extent at which TMR reduced the level of 
lipolysis is similar to the efficacy seen with PIC. 4G demonstrated a slight reduction in 
the level of glycerol release, however, it was not reduced to a significantly different level 
as compared to the control. In a stimulated, acute treatment (Figure 3.1 B) we observed 
significant reduction in lipolysis by PIC as well as TMR, with similar inhibition level. 4G 
also significantly reduced the level of glycerol release in a lipolysis-induced environment 
in contrast to a basal condition. Interestingly, we note that 3G was unable to significantly 
reduce lipolysis, in this condition with an acute treatment, although we did observe a 
slight reduction. Overall, we observed, as hypothesized, that other resveratrol metabolites 
were able to partially inhibit lipolysis. To our knowledge, this is the first report of the 
effect of different resveratrol metabolites and their effect on lipolysis with short treatment 
time. Collectively, these results demonstrate the rapid action that resveratrol metabolites 
have on lipolysis in mature adipocytes in vitro. 
The next question addressed was the impact of these resveratrol metabolites in an 
extended, chronic treatment in basal and stimulated conditions. A 24 hour treatment of 
the resveratrol metabolites at 50 µM was added to mature 3T3-L1 cells with greater than 
90% lipid accumulation. Compared to the control, all the metabolites examined, PIC, 
TMR, 3G, and 4G demonstrated lipolysis-lowering ability in a chronic, basal 
environment (Figure 3.2 A). PIC and TMR significantly reduced lipolysis at similar 
levels, consistent with an acute treatment. 3G and 4G significantly diminished the 
glycerol release the most. This suggests that efficacy of 3G and 4G is enhanced with a 
longer treatment time. In the literature, there is one report identifying RES enhancing the 
level of lipolysis through increase in free fatty acid (FFA) release in mature 3T3-L1 
adipocytes (Lasa et al. 2012b). Observed by Lasa, RES significantly increased FFA in 
both chronic (24 hours) basal and stimulated conditions, however, glycerol levels 
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remained unchanged. Consistent with this report, RES treated for 24 hours in the basal 
condition revealed no significant difference as compared to the control. However, we did 
not observe the same large induction detected by Lasa (Lasa et al. 2012b). There is 
greater variability observed with the chronic stimulated condition (Figure 3.2 B). Of the 
treatments, PIC and TMR alone were able to reduce lipolysis significantly. We observed 
similar levels between the control, 3G, and 4G. Interestingly, we observed a significant 
reduction in lipolysis by RES, contrasting with reported data. However, it must be noted 
that the concentration levels used in our experiment was half the dosage of that reported 
induction by RES. This may be a contributor to the discrepancy between the chronic, 
stimulated condition treatment of RES as well as the different lipolytic-stimulant utilized.  
The distinct reduction in glycerol release correlating to the partial inhibition of 
lipolysis by resveratrol metabolites is not unreasonable. Treatment with TMR 
demonstrated significant reductions in both acute and chronic conditions in both basal 
and stimulated conditions. This resveratrol analogue gave rise to great interest as it was 
able to cause an effect in levels similar to PIC. To our knowledge, TMR has not been 
studied in lipid metabolism, although it has been shown to have anti-cancer activities in a 
variety of other in vitro cell systems (Dias et al. 2013; Hsieh et al. 2011b; Pan et al. 2008). 
The structure of TMR, containing three methoxy groups, lends itself to be more lipophilic 
and making it more favorable to be studied in a cellular adipocyte system. Although there 
has been no report of resveratrol metabolites in lipolysis, 3G and 4G have been 
previously studied for their delipidating effect in both maturing and mature 3T3-L1 
adipocytes (Lasa et al. 2012a). It was reported that 3G was able to significantly reduce 
the TAG content in mature adipocytes upon a 24 hour treatment at both 10 and 25 µM. In 
comparison to a control, 3G was described as having slightly increased mRNA 
expression of ATGL and HSL levels, however this increase was not significant (Lasa et al. 
2012a). This previous report is consistent with our results in the chronic, stimulated 
condition, where 3G shows very little action in reducing lipolysis. 4G was observed in 
the same study to have action in reducing TAGs significantly both in maturing and 
mature adipocytes at 25 µM. 4G also faintly increased ATGL mRNA expression and 
significantly increased HSL (Lasa et al. 2012a). Like 3G, these reported findings for 4G 
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are similar to our observation in Figure 3.2 A; where there is a significant reduction in 
lipolysis. RES was additionally examined in this experiment to demonstrate the structure-
function differences that occur with slight molecular modifications. Although RES has 
been reported to significantly increase serum FFA in 3T3-L1 cells (Lasa et al. 2012b), it 
only slightly increased FFA release in SGBS cells in the basal condition, while glycerol 
levels remained unchanged in both cell lines. This is comparable to our results. Notably, 
SBGS are human adipocytes, and the effect in these cells are of higher resemblance to an 
actual human effect (Lasa et al. 2012b). Also, previously reported in our lab with 3T3-L1 
cells, lipolysis was unaffected by RES, showing no difference from control cells in 
glycerol release or FFA (Kwon, unpublished). RES has been show as most active at 
reducing TAG levels (Lasa et al. 2012a), while its metabolites maintain action in other 
functions; indicating that resveratrol metabolites maintain relevancy in reducing lipolysis.  
In obesity, there is increased level of basal lipolysis, as previously described, and 
in this system, that condition may be most similar to a chronic, stimulated condition in 
our in vitro model. Therefore in looking at these results (Figure 3.2 B), we see that PIC 
and TMR have the greatest potency in reducing the level of glycerol release. 3G and 4G 
did not elicit the same effectiveness and there is variability seen between basal and 
stimulated conditions. Additionally, 3G and 4G have already been studied in lipid 
metabolism with some emphasis of their role in the lipolytic pathway. For these reasons, 
we pursed the role of TMR in adipose function and studied deeper into identifying the 










Figure 3.1 Effect of resveratrol metabolites on acute release of glycerol on mature 
adipocytes. Glycerol release in 3T3-L1 mature adipocytes treated for 1.5 hours at day 10 
after differentiation in the presence of the vehicle (control [C]), dimethyl sulfoxide 
(DMSO), or at 50 µM with piceatannol (PIC), trans-   -trimethoxyresveratrol (TMR), 
resveratrol-3-O-glucuronide (3G), resveratrol--O-glucuronide (4G) in DMSO. 
Comparisons between each treatment with control; subjected to basal (A) and stimulated 
















































































Figure 3.2 Effect of resveratrol metabolites on chronic release of glycerol on mature 
adipocytes. Glycerol release in 3T3-L1 mature adipocytes treated for 24 hours at day 10 
after differentiation in the presence of the vehicle (control [C]), dimethyl sulfoxide 
(DMSO), or at 50 µM with resveratrol (RES), piceatannol (PIC), trans-   -
trimethoxyresveratrol (TMR), resveratrol-3-O-glucuronide (3G), resveratrol--O-
glucuronide (4G) in DMSO. Comparisons between each treatment with control; subjected 
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3.2.2 Impact of trans-   -trimethoxyresveratrol (TMR) on cell viability 
TMR has been shown to possess the capacity to inhibit cell viability as well as 
stimulate apoptosis in a variety of cell systems including colon, prostate, and breast 
tumors in vitro and in vivo (Dias et al. 2013; Hsieh et al. 2011a; Pan et al. 2008; Simoni 
et al. 2006). Therefore, we wanted to ensure the partial inhibition of lipolysis by TMR 
was not due to action inhibiting cell viability, but through other antilipolytic action. Thus, 
the MTT assay was used to determine the effect of TMR in both proliferating 3T3-L1 
preadipocytes along with mature adipocytes. Cells were treated with varying 
concentrations of TMR (0, 5, 10, 25, and 50 µM) for 24 hours. These conditions 
represent the maximum treatment concentration and time that was used in our study. 
Proliferating preadipocytes showed no significant reductions in cell viability (Figure 3.3). 
In fact with lower concentrations of TMR at 5 and 10 µM, we note slightly enhanced 
viability. At higher concentrations of TMR, 25 and 50 µM, we did observe some slight 
inhibition on viability, however these effects were not greater than 25% nor significant. 
Mature adipocytes were also examined. Two day, post-confluent cells were stimulated to 
differentiate with an adipogenic cocktail of DMI and grown to mature adipocytes with 
lipid accumulation. At day 10 after differentiation, cells were incubated with TMR and 
consistent with preadipocytes, TMR had very little effect on cell viability (Figure 3.4). At 
its highest concentration, TMR maintained the same level of cell viability as the control. 
Taken together, our results demonstrate that TMR does not contain cytotoxic effects in 
3T3-L1 preadipocytes or mature adipocytes, and this data suggests that the reduction of 







Figure 3.3 Effect of trans-   -trimethoxyresveratrol (TMR) on 3T3-L1 
proliferating cell viability. Post-confluent 3T3-L1 preadipocytes were incubated with 
various concentrations of TMR for 24 hours and the viability of these cells was assessed 



































Figure 3.4 Effect of trans-   -trimethoxyresveratrol (TMR) on mature 3T3-L1 
adipocyte cell viability. Mature 3T3-L1 adipocytes at day 8 after differentiation were 
incubated with various concentrations of TMR for 24 hours and the viability of these 
cells was assessed by MTT assay. Data are presented as means ± SEM, n=4. Not 
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3.2.3 TMR stability and intracellular localization 
In order attribute the effects observed to TMR, a stability assay was performed to 
understand its degradation pattern in DMEM media. This assay is necessary and often an 
overlooked factor, with some phenolic compounds undergoing reactions with the cell 
culture medium (Halliwell 2008; Long et al. 2010). Modifications in stability, chemical 
structure, and interactions with other biomolecules may affect molecular targets (Delmas 
et al. 2011). RES incubated in DMEM at 37oC results in some instability overtime (24 
hours); however amounts of hydrogen peroxide, indicative of oxidation, were not 
significant (Long et al. 2010). This demonstrates the benefit of TMR having a degree of 
protection against extensive metabolism or oxidation due to its methoxylation (Lin and 
Ho 2009). Currently, there is little information on the stability of resveratrol metabolites 
in reference to their biological effects (Delmas et al. 2011). Resveratrol metabolite, PIC, 
has been shown to be present more intact than that of RES when studied in rats 
(Setoguchi et al. 2014). The pharmacokinetic profile of TMR was evaluated in rat plasma 
and found to have greater plasma exposure, longer half-life and lower clearance 
compared to RES, however this model was with TMR fully dissolved in hydroxypropyl-
 -cyclodextrin (HP- -CyD) (Lin and Ho 2009). In our in vitro model, the stability of 
TMR was analyzed to ensure its efficacy. TMR was added to medium, incubated at 37oC, 
and collected at different time points (Figure 3.5). The half-life of TMR, as a percentage 
of the control, was determined to approximately 4 hours. Currently there are no published 
data on the stability of TMR in DMEM media, the closest comparison is relatively 
similar at approximately 5.8 hours seen in rat plasma dissolved in HP- -CyD (Lin and 
Ho 2009). Between 6 and 9 hours, TMR concentration was undermined, which suggests a 
degree of degradation. However, the majority of the experiments completed in this study 
were well within the range of 6 hours, with most common treatment times of 1.5 and 3 
hours.  
In determination of stability, we also wanted to identify where in the cell TMR 
localizes. Mature 3T3-L1 cells were treated with TMR and incubated for 3 hours at 37oC. 
Images of cells and accumulated lipid were captured by SRS imaging, while the 
fluorescence of TMR was photographed with TPEF (Figure 3.6). The fluorescence signal 
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of TMR is strong, and the green color (TMR) indicates its high intensity. These images 
allow us to see that TMR co-localizes very strongly with the LD. The merged picture of 
TMR and the LD demonstrate its lipophilicity and where its action may occur. 
Interestingly, images taken previously by our lab show RES and in the intracellular space 
of the cytosol (unpublished). Noting this, it distinctly sets apart TMR, in location and its 
action in the cell may be due to its more lipophilic structure. TMR has been described as 
being distributed in higher levels in major organs than in plasma and is highly likely to be 
found fat tissues (Dias et al. 2013). 
Collectively, although the stability of TMR in media is found in low levels after 6 
hours, it is important to note that TMR is highly located with the LD within 3 hours of 
treatment. This suggests that when given to the cells, much of TMR is taken up rapidly 
and can have action in cellular processes, such as lipolysis, within a short period of time 







Figure 3.5 Stability of trans-   -trimethoxyresveratrol (TMR) in DMEM media. 
TMR was added to serum free media at 50 µM and incubated at 37 C. Aliquots were 
collected at various incubation time points. Samples were quantified by fluorescence at 































      
        
Figure 3.6 Trans-   -trimethoxyresveratrol (TMR) intracellular localization in 
adipocyte. 3T3-L1 mature adipocytes treated for 3 hours at day 11 after differentiation in 
serum free DMEM media in the presence or absence of TMR (0 and 50 µM). Mature 
adipocytes were subjected to SRS imaging to visualize lipid droplet accumulation (red 
color) and TPEF imaging to observe intracellular TMR (green color). Image dimensions 





3.2.4 Dose-dependent effect of TMR on lipolysis in mature adipocytes 
TMR has been studied as an anti-cancer agent; however, its role in lipid 
metabolism has not yet been investigated. Here we elucidate its impact on 3T3-L1 mature 
adipocyte lipolysis and its underlying molecular mechanism. In order to achieve this, 
fully differentiated cells were treated at day 10 in the presence or absence of TMR at 
increasing concentrations. Based on MTT assay, each concentration up to 50 µM is non-
toxic and maintains no adverse effects on cell viability. Treatment of cells was done 
acutely at 1.5 hours. This is based on previous results which indicated TMR had a 
significant effect with a low treatment time. TMR was administered to cells at 0, 5, 10, 25, 
and 50 µM in both the basal and stimulated condition (Figure 3.7 A and B). In both 
conditions, TMR demonstrates significant, partial inhibition of lipolysis observed with 
reduced levels of glycerol released. This reduction in lipolysis is seen at each 
concentration of TMR. The efficacy of TMR and other resveratrol metabolites have been 
reported to show effects even at low concentrations (Hsieh et al. 2011a; Lasa et al. 
2012a). Identifying a low concentration threshold with adequate efficacy is critical for 
making animal and human physiological comparisons for dosage. Furthermore, 
identifying this dose-dependent response in glycerol release indicates another model 








Figure 3.7 Dose-dependent effect of trans-   -trimethoxyresveratrol (TMR) on 
release of glycerol on mature adipocytes. Glycerol release in 3T3-L1 mature adipocytes 
treated for 1.5 hours at day 10 after differentiation in the presence or absence of TMR (0, 
5, 10, 25, and 50 µM). Comparisons between each treatment with control; subjected to 
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3.2.5 Time-dependent impact of TMR on lipolysis in mature adipocytes 
In order to understand the difference between an acute and chronic treatment, we 
turned our attention to the aspect of time and the role it plays in affecting lipolysis 
inhibition by TMR. Most treatments of RES and its metabolites on 3T3-L1 cells were 
done a longer treatment times; a 24 hour treatment in mature adipocytes or treatment was 
given every 48 hours in maturing adipocytes (Lasa et al. 2012a; Lasa et al. 2012b). In one 
report by Lasa, were cells treated for a shorter, 12 hour time period with RES. As 
mentioned in the literature review, the lipolysis process, though a simplistic idea, it is a 
highly regulated, complex system (Zechner et al. 2012). The cascade of events which 
occur by proteins and different transcription factors may be altered in their action due to 
the amount time that the cell is exposed to an antilipolytic agent. We proposed that 
perhaps there is an optimal time that TMR is able to modulate the lipolysis process. 
TMR demonstrated an antilipolytic effect at 25 µM in glycerol release. We treated 
mature 3T3-L1 cells in the presence or absence of TMR (25 µM) for 3, 6, 21 and 24 
hours (Figure 3.8). We observed that TMR has a significant reduction in the glycerol 
release at an acute treatment time of 3 hours, and we also noted a significant difference at 
21 hours. Additionally, we also incubated mature adipocytes with 50 µM for 1.5 and 6 
hours, in both basal and stimulated conditions (Figure 3.9 A and B). Similarly, we note 
that the shorter, acute treatment of TMR is most effective in partially blunting glycerol 
release. These results indicate that TMR acts rapidly in influencing major components in 







Figure 3.8 Time-dependent effect of trans-   -trimethoxyresveratrol (TMR) on 
release of glycerol on mature adipocytes with 25 µM. Glycerol release in 3T3-L1 
mature adipocytes treated at different time points (1.5, 6, 21, and 24 hours) at day 10 after 
differentiation in the presence or absence of TMR (25 µM). Comparisons between each 
treatment with control; subjected to a basal conditions. Data are represented as means ± 
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Figure 3.9 Time-dependent effect of trans-   -trimethoxyresveratrol (TMR) on 
release of glycerol on mature adipocytes with 50 µM. Glycerol release in 3T3-L1 
mature adipocytes treated at different time points (1.5 and 6 hours) at day 10 after 
differentiation in the presence or absence of TMR (50 µM). Comparisons between each 
treatment with control; subjected to basal (A) and stimulated (B) conditions. Data are 










































































3.2.6 Mechanistic effect of TMR on lipolysis in mature adipocytes 
The next question we inquired involved the determination by what molecular 
mechanism does TMR elicit its partial inhibition of lipolysis. Lipolysis involves three 
different enzymes which work to hydrolyze LD TAGs into three FA and a glycerol 
backbone (Duncan et al. 2007; Zechner et al. 2012). This catabolic process and 
mobilization of NEFA into the bloodstream occurs during times of energy expenditure or 
fasting (Langin 2006a). As previously described, the first enzyme which acts primary on 
TAG is ATGL with activation by CGI-58, followed HSL which has high affinity to 
remove the second FA on DAG, and finally MGL acts to remove the final FA from the 
glycerol backbone (Ahmadian et al. 2010; Walther and Farese 2012). Formerly studied in 
our lab was the action of PIC on lipolysis. It has been shown that PIC works to partially 
inhibit lipolysis through protein degradation of ATGL and co-activator, CGI-58 (Figure 
3.10), primarily through activation of autophagy pathway targeting ATGL and CGI-58 
(Kwon, unpublished). Therefore, based on our results of PIC and TMR both inhibiting 
lipolysis at similar levels, the molecular mechanisms at which they suppress lipolysis 
may also be similar due to resemblance in their structure.  
Immunoblot analysis of lipolytic enzymes was done with mature 3T3-L1 
adipocytes that were treated in the presence or absence of TMR at varying concentrations 
(0, 5, 10, 25, and 50 µM) and PIC at 50 µM was used as a positive control. Western blot 
analysis was performed both in basal and stimulated conditions at an acute treatment time 
of 1.5 hours (Figure 3.11). In the basal condition, there is a dose-dependent response that 
mimics the effect seen in glycerol release. ATGL is observably reduced as compared to 
the control with different concentrations of TMR. Not surprisingly, we see that TMR is 
has greatest potency at its highest concentration of 50 µM. However, the level of ATGL 
reduction is not as substantial as PIC. Based on the quantification of band intensity 
(Figure 3.12 A), TMR is able to reduce ATGL protein expression by 40%, whereas PIC 
reduces it greater than 80%. TMR is also shows action in reducing CGI-58 protein 
expression. CGI-58 is necessary for activation and maximum stimulation of ATGL as 
well as regulation of the hydrolytic protein (Lass et al. 2006). TMR activity in the 
reducing CGI-58 is comparable to that of PIC, in which we see just over 50% reduced by 
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TMR and approximately 80% reduced by PIC. The second major lipolytic enzyme is 
HSL. Phosphorylation of HSL is the major regulator for activation of the enzyme as well 
as for the translocation to the surface of the LD (Schweiger et al. 2006). HSL 
phosphorylation occurs at multiple sites, but phosphorylation at serine-660 is responsible 
for interfacial activation and hydrolytic action of DAG (Walther and Farese 2012). 
Phosphorylation of HSL (pHSL) was also analyzed. TMR action of pHSL was 
surprisingly different than PIC in the basal condition. We observed slight reduction in the 
level of pHSL by TMR, whereas we see a large induction of pHSL of PIC. Overall, the 
level of reduction in lipolysis by glycerol release of TMR and PIC is very similar, yet the 
reduction level of ATGL and CGI-58 is greater in PIC than TMR. This discrepancy may 
be due to TMRs slight action inhibiting HSL activation in an acute basal treatment.   
In the acute stimulated condition, we observe a similar, more pronounced trend in 
the action of TMR on lipolytic enzymes. ATGL protein expression is greatly reduced by 
TMR, similar to PIC (Figure 3.11 B) at approximately 80% (Figure 3.12 B). TMR only 
reduced CGI-58 by 20% as compared to the control, whereas we still observe a large 
reduction by PIC. The pHSL in this condition by TMR is slightly reduced maintaining a 
similar trend as seen in the basal condition. Again, this contrasts with action by PIC, 
which increases pHSL. This data suggests that TMR action on lipolysis in an acute 
condition is predominantly through reduction of protein expression of ATGL. However, 
it is worth noting, that TMR does have small action in reducing both CGI-58 and pHSL. 
The ability of TMR to interact and affect, at least in part, these major lipolytic enzymes 
may be attributed to its capacity to locate with the LD. The lipolysis process is occurs at 
the surface of the LD, accordingly, the catabolic enzymes are equipped with a 
hydrophobic region which allows binding (Duncan et al. 2007). Advantageously, the 
structure of TMR lends itself to be more lipophilic, and perhaps have greater versatility 
surrounding the LD.  
To further confirm that greatest effect of TMR action is seen with an acute 
treatment. Immunoblot analysis was performed on mature murine 3T3-L1 adipocytes 
which were treated for 3 hours in the presence or absence of TMR at 0, 25, and 50 µM 
concentrations (Figure 3.13). We observed large reductions in the levels of ATGL and 
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CGI-58 protein expression (Figure 3.14). These results show the reduction of lipolytic 
enzymes by TMR dose-dependently. The reductions in protein expression are similar to 
the levels observed by PIC with a 1.5 hour treatment. TMR, at 50 µM was able to 
effectively reduce ATGL expression by approximately 80% and CGI-58 by 70%. The 
level of pHSL was also consistent with our previous results, indicting slight action in 
blocking its phosphorylation. These data suggest the largest reduction of lipolytic 
enzymes observed by TMR at 3 hours. For comparison, TMR was treated for 6 hours on 
mature adipocytes and immunoblot analysis was done to observe its effects on enzyme 
expression (Figure 3.15). Observably, we note a reduction in ATGL and CGI-58 levels. 
Yet when analyzing the quantification of the band intensity, we see that the detected 
effect is not as large compared to a 3 hour treatment (Figure 3.16). TMR demonstrates 
reduction of ATGL protein expression by 40% and reduces CGI-58 protein level by 25%. 
Conversely, we see an upregulation of pHSL as compared to the control. Importantly, the 
data suggests that the most effective treatment of time of TMR is acute, at 3 hours, and 
time does play a role on the level of lipolytic inhibition.   
In an attempt to further our understanding of the effect of TMR on lipolytic 
protein expression, we examined TMR in a basal, chronic condition. 3T3-L1 mature 
adipocytes were treated with different concentrations of TMR (0, 5, 10, 25 and 50 µM) 
for 24 hours and protein expression was analyzed with immunoblotting (Figure 3.17). 
Our protein expression levels of cells treated with TMR as compared to the control are 
reduced, however not to the same degree observed in an acute treatment of 3 hours. Here 
we observe an approximately 20% reduction in ATGL protein expression by TMR only 
at its highest concentration of 50 µM (Figure 3.18). PIC still maintains chronic efficacy 
in its degradative action of ATGL. CGI-58 protein expression had a similar trend as 
ATGL; TMR induced a slight reduction while PIC sustained its degradation (data not 
shown). pHSL after a 24 hour treatment was highly increased with TMR (25 and 50 µM) 
and PIC treatment with a 3-fold increase. This data suggests that there may be a 
compensatory effect that occurs in a chronic treatment of TMR. And although, glycerol 
release is still partially inhibited with a 24 hour treatment by TMR, within the cell only 
slight reductions in ATGL and CGI-58 are seen with pHSL being upregulated to possibly 
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compensate for the extended time and need for an energy substrate. Taken together, our 
results demonstrate TMR acts in a similar manner as PIC and the molecular mechanism 
at which TMR partially inhibits lipolysis is primarily with reduction of ATGL, with slight 
inhibition action on both CGI-58 and pHSL. This effect of TMR is seen at a greater 
potency in an acute treatment.   
It has been reported in vivo high fat diet (HFD)-induced obesity disrupts the 
controlling pathways and causes changes in lipolytic protein expression and signaling 
(Gaidhu et al. 2010). In an obesogenic condition, it was noted that several key lipolytic 
elements are altered; this includes upregulation of ATGL and CGI-58 and down 
regulation of HSL and perilipin. This culminates in an increased level of basal lipolysis 
with alterations in the molecular regulation of FA metabolism and lipolysis, leading to 
increased metabolic dysfunctions (Gaidhu et al. 2010). Defects in the metabolic 
regulatory system ultimately results in severe consequences, as reviewed earlier, 
including increased levels of circulating NEFA and insulin resistance leading to ectopic 
fat distribution (Despres and Lemieux 2006). Here we describe an in vitro system with 
dietary compounds effects can help to attenuate some of the dysfunctional action in 
lipolysis. Our results demonstrate an altered cellular environment that would increase the 
health of a HFD-obesogenic condition. We observe reduction in glycerol release and 
definitive down regulation of ATGL and CGI-58, and slight reductions in the pHSL by 
TMR. This action is occurs acutely and is specific to the surface of LD, where TMR 
locates. The data suggests that TMR helps to modulate the first, rate-limiting step of 













Figure 3.11 Dose-dependent acute effect of trans-   -trimethoxyresveratrol 
(TMR) on lipolytic enzymes in 3T3-L1 mature adipocytes. 3T3-L1 mature adipocytes 
were incubated in the presence or absence of TMR at various concentrations (0, 5, 10, 25, 
50 µM) or piceatannol (PIC) at 50 µM for 1.5 hours in the basal and stimulated 
conditions. Cells in stimulated condition were incubated with isoproterenol (ISP). The 
cells were collected and protein samples were prepared. Protein levels of ATGL, CGI-58, 
and phosphorylated HSL (Ser660) in these cells were detected by immunoblot assay 
using their specific antibodies and -actin as a loading control. The experiment was 
repeated at least twice with similar results.  
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Figure 3.12 Quantification of immunoblot [shown in Figure 3.11] Film was scanned 
and protein band intensity was quantified with NIH ImageJ software (ver 1.45S), 
normalized to ban   	 
-actin. Cells were subjected to basal (A) and stimulated 








































































Figure 3.13 Three hour effect of trans-   -trimethoxyresveratrol (TMR) on 
lipolytic enzymes in 3T3-L1 mature adipocytes. 3T3-L1 mature adipocytes were 
incubated in the presence or absence of TMR at various concentrations (0, 25, 50 µM) for 
3 hours in a basal condition. The cells were collected and protein samples were prepared. 
Protein levels of ATGL, CGI-58, and phosphorylated HSL (Ser660) in these cells were 
detected by immunoblot assay using their specific antibodies and -actin as a loading 
control. The experiment was repeated at least twice with similar results.  
  











Figure 3.14 Quantification of immunoblot [shown in Figure 3.13] Film was scanned 
and protein band intensity was quantified with NIH ImageJ software (ver 1.45S), 
 	
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Figure 3.15 Six hour effect of trans-   -trimethoxyresveratrol (TMR) on lipolytic 
enzymes in 3T3-L1 mature adipocytes. 3T3-L1 mature adipocytes were incubated in 
the presence or absence of TMR at various concentrations (0, 50 µM) for 6 hours in a 
basal condition. The cells were collected and protein samples were prepared. Protein 
levels of ATGL, CGI-58, and phosphorylated HSL (Ser660) in these cells were detected 
by immunoblot assay using their specific antibodies and -actin as a loading control.  
  











Figure 3.16 Quantification of immunoblot [shown in Figure 3.15] Film was scanned 
and protein band intensity was quantified with NIH ImageJ software (ver 1.45S), 
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Figure 3.17 Dose-dependent chronic effect of trans-   -trimethoxyresveratrol 
(TMR) on lipolytic enzymes in 3T3-L1 mature adipocytes. 3T3-L1 mature adipocytes 
were incubated in the presence or absence of TMR at various concentrations (0, 5, 10, 25, 
50 µM) or piceatannol (PIC) at 50 µM for 24 hours in a basal condition. The cells were 
collected and protein samples were prepared. Protein levels of ATGL and phosphorylated 
HSL (Ser660) in these cells were detected by immunoblot assay using their specific 
antibodies and -actin as a loading control. The experiment was repeated at least twice 
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Figure 3.18 Quantification of immunoblot [shown in Figure 3.17] Film was scanned 
and protein band intensity was quantified with NIH ImageJ software (ver 1.45S), 
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3.2.7 TMR partially inhibits lipolysis in mature adipocytes via protein reduction 
In order to observe and confirm the overall effect that TMR exhibits on mature 
adipocytes. We treated 3T3-L1 cells in the presence or absence of TMR (0, 25, 50 µM) 
for 3 hours in both a basal and stimulated condition (Figure 3.19). Here we validate 
results consistent with our previous data. TMR is able to modulate lipolysis in both 
conditions via reductions in protein expression of ATGL and CGI-58. To note, TMR is 
highly potent in the basal condition with significant reductions of ATGL at 70% and 60 % 
of CGI-58 (Figure 3.20 A). TMR also showed a slight inhibition of pHSL, consistent 
with previous 3 hour treatments. In the stimulated condition, we observe that TMR is able 
to reduce ATGL and CGI-58, yet the levels of reduction are not as pronounced as in the 
basal state (Figure 3.20 B). We detect 25% and 35% reduction in protein expression 
levels of ATGL and CGI-58, respectively. Also, pHSL was slightly increased compared 
to the control. This may suggest some increased signaling or alternative route the cell is 
trying to control with HSL, because although HSL mainly acts on DAG, it does maintain 
affinity for hydrolyzing TAG (Duncan et al. 2007). Nonetheless, these results provide 
confirmatory evidence on TMR partial inhibitory action of lipolysis through reduction of 
lipolytic enzymes and its modulating specificity in lipid metabolism.  
Our study proposes significant, partial inhibition of mature adipocyte lipolysis by 
TMR requires a concentration up to 50 µM in vitro. Our data suggests that the 
physiological condition of mature adipocytes may be more sensitive to acute exposure to 
circulating levels of TMR, which exerts a beneficial function in a metabolic 
dysfunctional environment. The rate of NEFA release of adipose tissue is strongly 
associated with insulin resistance and type 2 diabetes (Lass et al. 2006). Therefore 
identifying a potential dietary compound, such as TMR, as an antilipolytic agent, which 
aids in modulating this process may be a beneficial therapeutic strategy. Given the 
importance of the lipolysis process in overall energy homeostasis, it imperative to 
mention that with treatment of TMR, we do not observe full inhibition of glycerol release 
and protein expression. It has been reported that patients with complete deficiencies in 
either ATGL or CGI-58 lead to defective lipolytic catabolism, resulting in accumulation 
of neutral lipid storage and an obese phenotype (Lass et al. 2006). Moreover, the partial 
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Figure 3.19 Acute effect of trans-   -trimethoxyresveratrol (TMR) on lipolytic 
enzymes in 3T3-L1 mature adipocytes. 3T3-L1 mature adipocytes were incubated in 
the presence or absence of TMR at various concentrations (0, 25, 50 µM) for 3 hours in 
the basal and stimulated conditions. Cells in stimulated condition were incubated with 
forskolin (FSK). The cells were collected and protein samples were prepared. Protein 
levels of ATGL, CGI-58, and phosphorylated HSL (Ser660) in these cells were detected 
by immunoblot assay using their specific antibodies and -actin as a loading control. The 
experiment was repeated at least twice with similar results.  
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Figure 3.20 Quantification of immunoblot [shown in Figure 3.19] Film was scanned 
and protein band intensity was quantified with NIH ImageJ software (ver 1.45S), 
 	
  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3.2.8 Impact of TMR on lipolytic gene expression 
There is large importance in understanding how specific lipolytic enzyme 
manifestation is effected by dietary compounds, such as TMR. However, other regulatory 
mechanisms take place in modulating the transcription and translation of specific lipases. 
Therefore, in order to understand if TMR acts at these levels, relative mRNA expression 
of lipolytic lipases was also analyzed (Figure 3.21). Here we observed as significant 
reduction in the relative expression of ATGL, as well as with the lipid associated protein, 
perilipin. We note that a treatment with TMR shows a trend of reduction in both CGI-58 
and HSL expression levels. The down regulation of these genes is not surprising as it has 
been previously reported that RES, shown to target ATGL, displayed upregulation in 
both protein and relative mRNA expression. It was also noted, however, that RES does 
not have any noticeable effect on HSL (Lasa et al. 2012b). Also reported, the resveratrol 
metabolite, resveratrol-3-O-sulfate (3S), displayed a reducing trend in HSL mRNA 
expression levels (Lasa et al. 2012a). Collectively, our protein analysis in combination 
with our mRNA analysis of lipolytic enzymes demonstrates a profound effect of TMR 
and its modulation of lipolysis. Our study observed that TMR reduced glycerol release to 
similar potency as PIC. And although we show that TMR also plays a role in the 
reduction of protein expression of ATGL and CGI-58, it was not seen to the same degree 
as PIC. Our relative mRNA expression of lipolytic enzyme illustrates another piece of the 
puzzle, suggesting TMR has some transcriptional activity regarding these enzymes.  
In summary, our study including molecular imaging and biochemical analysis 
provides evidence that TMR is significant in partially inhibiting mature adipocyte 
lipolysis through the reduction of lipolytic enzymes, possibly via mediation of protein 
degradation, and potentially having activity which acutely affects enzymatic transcription. 
Our results also indicate that the structure of TMR allows its co-localization with the 
hydrophobic LD and may attribute to its high activity in lipid metabolism. Collectively, 
this study elicits new findings that TMR modulates lipolytic activity in murine adipocytes 
in vitro and can support further investigations of therapeutic approaches for metabolic 






Figure 3.21 Effect of trans-   -trimethoxyresveratrol (TMR) on lipolytic 
transcription factor expression. 3T3-L1 mature adipocytes were incubated in the 
presence or absence of TMR (50 µM) for 3 hours in a basal condition. The cells were 
collected on day 10 and samples were prepared and subjected to quantitative gene 
expression analysis of ATGL, CGI-58, HSL, and perilipin by real-time (RT)-PCR. The 
signals were normalized by -actin as an internal control. The values are displayed as 
fold change compared to the control; value arbitrarily set to 1. Data are presented as 
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3.3 Adipose function: Lipogenesis 
As described in the review of the literature, during the terminal phase of 
adipogenesis, genes are encoded which result in the generation of FA and TAG (Kim et 
al. 2013). The process of carbon movement and series of enzymatic reactions yielding the 
production of FA is known as de novo lipogenesis (Ameer et al. 2014). The formation of 
TAG is also conducted by enzymes which involves a series of esterification of FA 
moieties to a glycerol backbone (Farese and Walther 2009). The molecular level of gene 
expression of these specific enzymes as well as adipokines secreted are tightly regulated 
and increased during TAG formation (Kim et al. 2013).  
 Dietary and molecular control of lipogenesis may be a potential target to prevent 
adipose mass increase and the development of obesity and its associated diseases. Yet, 
complete inhibition of lipid accumulation in adipocytes could lead to severe negative 
consequences including hypertrophy and or increased storage of TAGs in non-adipose 
tissues (Kim et al. 2013). Approaches involving increasing overall energy expenditure 
through increased activity of thermogenesis and fatty acid oxidation (FAO) may be an 
alternative route to positively affect obesity. The molecular mechanisms involved in the 
regulation of adipocyte differentiation and lipid accumulation can be widely altered by 
addition of bioactive dietary compounds. Furthermore, utilizing phytochemicals as a 
means to modulate obesity-preventing cellular metabolic pathways may be used as a 
therapeutic strategy (Jeong et al. 2012).  
 
3.3.1 Impact of TMR on adipocyte differentiation and lipid accumulation 
TMR has been shown in other cellular system to have efficacy, acting as an anti-
cancer agent and can induce apoptosis (Dias et al. 2013; Pan et al. 2008). However, as 
reviewed in the literature, the action of phytochemicals is dependent on the function 
being analyzed. Currently, resveratrol metabolites have not been extensively studied in 
lipid metabolism; however, there is one report which details their role in adipogenesis 
and lipid accumulation. Lasa reports that treatment of 4G and 3S on maturing 3T3-L1 
cells from day 0 to day 8, results in a significant reduction of relative TAG content (Lasa 
et al. 2012a). PIC has also been shown to inhibit adipogenesis through modulation of 
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MCE as well as through insulin receptor-dependent insulin signaling during the early 
stage of differentiation (Kwon et al. 2012). Based on our results, TMR has specific action 
in adipose function, specifically lipolysis, but its role in obesity development has not yet 
been elucidated. Also, because other resveratrol metabolites have demonstrated an effect 
on lipid accumulation, we hypothesize that TMR may also play a role in lipogenesis. In 
order to understand the function of TMR on lipid accumulation, we first examined the 
effect of TMR on the differentiation process in 3T3-L1 preadipocytes. Two day post-
confluent preadipocytes were treated in the presence or absence of TMR (0 and 50 µM) 
and an adipogenic cocktail (DMI). Differentiating cells were treated with TMR every two 
days and were collected on day 6 after differentiation and lipid accumulation was 
quantified with ORO staining (Figure 3.22 A). Observably, there does not seem a 
dramatic reduction in lipid accumulation by TMR. Upon further inspection, we note that 
the sizes of the LDs in cells treated with TMR are slightly reduced. However, 
quantification of ORO stained intracellular LD was of no significance (Figure 3.22 B). 
Upon further confirmation of the effect TMR has on lipid accumulation, this experiment 
was repeated, yielding a large sample size (n=24). The repetition of this experiment was 
slightly contrasting with previous results we observed, in which we did see a reduction in 
LD formation (data not shown). Collectively, the lipid accumulation between the control 
and TMR are similar,    	










3.3.2 Impact of TMR on maturing adipocyte gene expression 
As mentioned in the literature review, adipogenesis is a highly regulated program 
in which the cascade of transcription factors are stimulated and activated leading to 
terminal differentiation and ultimately developed LD (Cornelius et al. 1994). There is 
high coordination of gene expression events that occur and enhance the activity of de 
novo lipogenic enzymes and increase lipid accumulation (Rosen and MacDougald 2006). 
It is important to note, that although PIC and 3S have been reported to have significant 
action in reducing adipogenic gene expression markers of C/  and , other 
resveratrol metabolites, 4G and 3G demonstrated no significant difference from the 
control, and actually trended toward increasing these markers (Kwon et al. 2012; Lasa et 
al. 2012a).  
In order to investigate the trend of slightly reduced lipid accumulation in maturing 
3T3-L1 adipocytes by TMR, we analyzed gene expression to understand if modulation 
occurred by TMR treatment. We wanted to determine if TMR was altering different gene 
expression markers during differentiation using quantitative real time RT-PCR. 3T3-L1 
preadipocytes were stimulated to differentiate in the presence or absence of TMR at 
varying concentrations (0, 10, 25, and 50 µM) and treated every two days until collected 
on day six after differentiation. The gene expression profiles of several different 
functional adipose markers are discussed below.  
 
3.3.2.1 De novo lipogenesis 
As previously discussed in the literature review, the cascade of de novo 
lipogenesis involves series of reactions performed by enzymes which construct FA and 
generate TAG (Farese and Walther 2009) 		
      
of adipocyte differentiation for its binding to fat specific enhancers. TMR at 50 µM 
showed no significant difference in mRNA expression compared to the control (Figure 
3.23 A). This data is consistent with reported data of RES, 3G, and 4G in which there 
was no significant change in  levels of maturing adipocytes (Lasa et al. 2012a). 
FAS, the major enzyme accounting for FA biogenesis, is dose dependently, and 
significantly upregulated by TMR (Figure 3.23 B). ACC is also upregulated significantly 
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by the highest concentration of TMR (50 µM) indicating increased production of 
malonyl-CoA to be used as substrate for FAS (Figure 2.23 C). We observed upregulation 
of MGAT1 and DGAT2, but there is no significant change in SCD-1 or SREBP1c (Figure 
2.23 D-G). It is interesting to observe upregulation in genes that are involved in the 
production of FA and TAG synthesis, due to our previous collected data that 
demonstrates no significant induction in LD accumulation. This expression of lipogenic 
genes poses a thought-provoking question: how does TMR upregulate de novo 
lipogenesis genes and yet the level of lipid accumulation is unchanged and trends toward 
a slight reduction? To begin to answer this question, we looked at the previous report 
with resveratrol metabolites and their effect on ACC and FAS. Interestingly, 3T3-L1 
mature adipocytes were subjected gene expression analysis of ACC and FAS after a 24 
hour treatment of 10 µM of RES, 4G, 3G and 3S (Lasa et al. 2012a). ACC levels trended 
increasingly, although not significant, by RES, 3G, and 4G. The level of FAS expression 
was significantly reduced by 3G, however RES demonstrated an almost 1.5 fold increase 
as compared to the control (not significant). Nonetheless, the action seen by RES is 
comparable to that observed by TMR. In mature adipocytes, RES significantly reduced 
TAG content yet had a trending increase in gene expression levels of FAS (Lasa et al. 
2012a). Although the authors do not comment on this occurrence, they did show 
increased levels of ATGL expression, which could indicate that RES has a higher capacity 
for energy expenditure through catabolic processes. In order to see if this is the case in 
our study and to fully understand this phenomenon in regards to TMR and its effect on 
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F      G 
  
Figure 3.23 Dose-dependent effect of trans-   -trimethoxyresveratrol (TMR) on 
de novo lipogenic marker gene expression. 3T3-L1 preadipocytes were subjected to 
adipocyte differentiation and an adipogenic cocktail (DMI). Cells were incubated in the 
presence of dimethyl sulfoxide (DMSO) or various concentrations of TMR (0, 10, 25, 
and 50 µM) in DMSO for 6 days. The cellular total RNA was extracted and subjected to 
RT-	 
       ff µM), (B) FAS, (C) ACC, (D) SCD1, 
(E) MGAT1, (F) DGAT2, and (G) SREBP1c were quantified and normalized with the 
fi flffi ! !" #-actin. The values are displayed as fold change compared to the 
control; value arbitrarily set to 1. Data are presented as relative fold induction means ± 






























































With TMR demonstrating a role in the marked increases in the lipogenic 
transcription program, we wanted to further investigate its effect on maturing adipocyte 
adipokine expression. Because adipose tissue is an endocrine organ, it has the capacity to 
secrete adipokines affecting metabolic pathways and energy homeostasis (Kershaw and 
Flier 2004). Therefore, we looked at four different adipokine gene expression profiles in 
cells treated with TMR to elucidate its potential involvement. Resistin, adiponectin, and 
adipsin were significantly upregulated, while the leptin was significantly reduced (Figure 
3.24 A-D). First of all, resistin expression is induced during adipocyte differentiation and 
its levels are increased in diet-induced obesity and suppressed by insulin in 3T3-L1 
adipocytes (Haugen et al. 2001) (Steppan et al. 2001). TMR demonstrated an increase in 
resistin. Its physiological function is to help regulate glucose tolerance and act as an 
adaptive response (Shojima et al. 2002). Comparatively, although in a different system, 
Mercader observed a 20 hour treatment of RES in mature adipocytes reduced resistin 
expression (Mercader et al. 2011). Leptin plays an important role in regulating food 
intake, energy expenditure, and physiologically when leptin plasma levels are increased, 
insulin secretion is inhibited (Cases et al. 2001). A reduced leptin concentration signals 
initiation for a starvation response (Ahima et al. 1996). Our results indicate a slight, 
significant reduction in the gene expression of leptin by TMR. This is similar to other 
published data with RES, which in maturing preadipocytes significantly reduces leptin 
expression (Eseberri et al. 2013) as well as rat adipocytes had reduced leptin secretion 
with RES treatment (Szkudelska et al. 2009). It was also noted that reduced leptin levels 
may be in part due to increased cAMP in fat cells, which could result in a parallel rise in 
lipolysis (Szkudelska et al. 2009). Our data suggests that the reduction in leptin levels by 
TMR may induce increased energy expenditure in the cells. Adiponectin is largely 
present in healthy human plasma and significantly lowered in obese subjects (Arita et al. 
1999). It is an important modulator in lipid metabolism and is known to increase insulin 
sensitivity as well as increase FAO (Fasshauer et al. 2002b). TMR dose-dependently 
increases adiponectin expression significantly. This induction is consistent with the effect 
of other resveratrol metabolites in maturing adipocytes including 3G, 4G, and 3S 
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(Eseberri et al. 2013). Finally, adipsin is found in high levels in adipose tissue and its 
expression has been shown to be greatly reduced in obese mice, while increased levels 
are associated with a catabolic state in normal rodents (Flier et al. 1987; White et al. 
1992). TMR effectively increases the expression of adipsin in 3T3-L1 maturing 
adipocytes which is consistent with an increased energy expenditure state. Collectively, 
the effect of TMR on adipokine gene expression is representative of cells which have 
altered lipid metabolism in that they have a higher propensity to expend energy. Taken 
together, this upregulation of adipokine gene expression, specifically adiponectin and 
adipsin, and down regulation of leptin possibly indicate an enhanced catabolic state 
which may result in reduced lipid accumulation.   
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Figure 3.24 Dose-dependent effect of trans-   -trimethoxyresveratrol (TMR) on 
adipokine gene expression. 3T3-L1 preadipocytes were subjected to adipocyte 
differentiation and an adipogenic cocktail. Cells were incubated in the presence of 
dimethyl sulfoxide (DMSO) or various concentrations of TMR (0, 10, 25, and 50 µM) in 
DMSO for 6 days. The cellular total RNA was extracted and subjected to RT-PCR. The 
mRNA levels of (A) Resistin, (B) Leptin, (C) Adiponectin, and (D) Adipsin were 
	
 	 	 
 
 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	 	 -actin. Data are presented as 
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To further investigate the overall effect of TMR on maturing adipocytes, lipolytic 
gene expression was analyzed to determine if catabolic processes were induced. ATGL, a 
major, rate-limiting step in the lipolysis was dose-dependently and significantly increased 
(Figure 3.25 A). Perilipin, a LD associated protein was also significantly increased when 
treated with 50 µM TMR (Figure 3.25 B). This transcriptional regulation by TMR 
demonstrates its ability to increased catabolic processes. This data represents that the 
action observed is highly dependent on the function being analyzed. TMR acts to increase 
energy expenditure in maturing adipocytes. Comparably, there is no report of other 
resveratrol metabolites concerning lipolytic gene expression in development stage of 
lipogenesis. Taken together, this data suggests that TMR modulates lipolytic transcription 
in maturing adipocytes which may be contributing factor of a trend toward a lessened 
lipid accumulation and size during development. Th    	
     
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Figure 3.25 Dose-dependent effect of trans-   -trimethoxyresveratrol (TMR) on 
lipogenic gene expression. 3T3-L1 preadipocytes were subjected to adipocyte 
differentiation and an adipogenic cocktail. Cells were incubated in the presence of 
dimethyl sulfoxide (DMSO) or various concentrations of TMR (0, 10, 25 and 50 µM) in 
DMSO for 6 days. The cellular total RNA was extracted and subjected to RT-PCR. The 
mRNA levels of (A) ATGL and (B) Perilipin (0 and 50 µM) were quantified and 
	
      -actin. Data are presented as relative fold 
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3.3.2.4 Mitochondrial biogenesis 
TMR showed an ability to increase catabolic process transcriptional activity; 
therefore we wanted to explore its effect in mitochondrial biogenesis. We identified three 
genes which are highly involved in the biogenesis of the mitochondria including 
mitochondrial transcription factor A (Tfam) and nuclear respiratory factors 1 (NRF1) 
and 2 (NRF2) (Figure 3.26 A-C). As energy demands of the cell can change through the 
process of differentiation, mitochondrial content is variable and can increase based on 
different physiological conditions, including adaptive thermogenesis (Goffart and 
Wiesner 2003). Although 95% of the genes required for mitochondrial biogenesis are 
encoded inside the nucleus, regulation of these genes are controlled by transcriptional 
mechanisms (Goffart and Wiesner 2003). Tfam activation is dependent on NRF1 and 
NRF2, and is an important transcriptional activator stimulating specific mitochondrial 
transcription initiation as well as mitochondrial DNA maintenance (Escriva et al. 1999). 
Tfam protein controls mitochondrial DNA copy number and has been shown to be vital 
for embryonic development and biogenesis (Escriva et al. 1999). TMR showed a slight, 
significant increase in Tfam, supporting mitochondrial biogenesis, as well as 
demonstrated significant increases in both NRF1 and NRF2. The NRFs have been 
reported to activate transcription of many genes involved in respiratory chain functions as 
well as regulating Tfam, translocating and activating the mitochondria and its replication 
and transcription (Wu et al. 1999a). NRF1 is important for mitochondrial haem synthesis 
and protein import into the mitochondria. It plays an important role in the coordination of 
nuclear and mitochondrial gene expression acting as a transcriptional activator for Tfam 
and in MRP endonuclease, which in required for mitochondrial DNA transcription 
(Goffart and Wiesner 2003). NRF1 also is critically involved in mitochondrial integrity 
and functioning (Goffart and Wiesner 2003). NRF2 binds to specific target sequences in 
the promoter region of a large number of nuclear encoded mitochondrial genes (Goffart 
and Wiesner 2003), and is responsible for the activity and expression of mitochondrial 
subunits (Virbasius and Scarpulla 1994). Our data suggest that TMR may be involved in 
altering and enhancing the coordinated expression of the genes that regulate 
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mitochondrial biogenesis pathway and may effective in increasing oxidative metabolism 









Figure 3.26 Dose-dependent effect of trans-   -trimethoxyresveratrol (TMR) on 
mitochondrial biogenesis marker gene expression. 3T3-L1 preadipocytes were 
subjected to adipocyte differentiation and an adipogenic cocktail. Cells were incubated in 
the presence of dimethyl sulfoxide (DMSO) or various concentrations of TMR (0, 10, 25, 
and 50 µM) in DMSO for 6 days. The cellular total RNA was extracted and subjected to 
RT-PCR. The mRNA levels of (A) Tfam, (B) NRF1, and (C) NRF2 were quantified and 
	
      -actin. Data are presented as relative fold 
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3.3.2.5 Fatty acid oxidation 
Genetic alteration in adipocyte metabolism has global implications in overall 
energy homeostasis; and increases in FAO in WAT has been suggested as a way to 
reduce adiposity (Rosen and Spiegelman 2006). Since TMR showed inductions in 
mitochondrial biogenesis gene expression, we proposed that it may also demonstrate 
upregulation of genes involved in FAO. Our findings show that TMR significantly 
increased MCAD expression, yet at its highest concentration, showed no change 
compared to the control in CPT1 (Figure 3.27 A and B). Increases in CPT1 and MCAD 
expression exert important effects in  -oxidation due to the nature that these two proteins 
act as the controlling, limiting steps in the process (Tiraby et al. 2003). Importantly, 
uncoupling protein 1 (UCP1) upregulation and its activity in uncoupling cells to undergo 
FAO without kinetic limitation by respiratory control (Tiraby et al. 2003). TMR was able 
to increase the expression of MCAD, a rate limiting enzyme involved in mitochondrial 
FAO (Mottillo et al. 2012), which is consistent with our observation of trending toward 
reductions in TAG content and TMRs proposed effect to allow the cell to maintain a 
higher capacity to burn energy. Yet, we did not see a similar induction with CPT1, 
another rate limiting enzyme highly involved in FAO by mitochondria. It is worth noting 
that an analogous phenomenon was also observed when RES was treated in mature 
adipocytes (Mercader et al. 2011). Overall a reduction in TAG content was observed with 
RES, yet of the two FAO genes examined, RIP 140 and CPT1-L, there was a significant 
increase in only one gene expression profile, while the other showed no difference from 
control. Nonetheless, our data suggests TMR directly promotes transcriptional 
remodeling in maturing adipocytes and trends toward increasing oxidative metabolism. 
Regulation of gene expression of -cocactivator- 	
- and UCP1 have 
potential to increase the capacity of FAO (Tiraby et al. 2003). TMR may have activity in 
increasing the expression and activation of PGC-

in adipocytes, which then could 
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Figure 3.27 Dose-dependent effect of trans-   -trimethoxyresveratrol (TMR) on 
fatty acid oxidation (FAO) marker gene expression. 3T3-L1 preadipocytes were 
subjected to adipocyte differentiation and an adipogenic cocktail. Cells were incubated in 
the presence of dimethyl sulfoxide (DMSO) or various concentrations of TMR (0, 10, 25, 
and 50 µM) in DMSO for 6 days. The cellular total RNA was extracted and subjected to 
RT-PCR. The mRNA levels of (A) MCAD and (B) CPT1 were quantified and 
normalized with the house ke	
 
	 -actin. Data are presented as relative fold 
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The impact of TMR gives evidence that is complicatedly involved in altering the 
normal functions of the cell. To gain more insight as to what is happening 
transcriptionally, we analyzed thermogenic marker gene expression in these cells. TMR 
significantly increases both UCP-1 and PGC-  (Figure 3.28 A and B). UCP1 is highly 
abundant in the mitochondria of BAT and when activated has the ability to short circuit 
the electrochemical gradient driving ATP synthesis, and consequently stimulates 
respiratory chain action (Harms and Seale 2013). UCP1 biosynthesis is highly regulated 
at the transcription level, and increases cAMP, a primary trigger of UCP1 (Ricquier 
2011). It has been known that WAT can contain cells which express increased levels of 
UCP and have the ability to take on multi-locular characteristics and pathways which 
promote increased cAMP levels (Wu et al. 2012). Our data shows that treatment of TMR 
increases UCP1 expression, suggesting that it may play a role in increasing the 
thermogenic capacity of the cell. In coordination with this increase in UCP1, we also 




 is seen at high levels in BAT and can also be 
induced upon cold exposure or stimulated -adrenergic pathways (Rosen and Spiegelman 
2006). In WAT, PGC- 	
  	
     	    	
including mitochondrial biogenesis and UCP1 action (Rosen and Spiegelman 2006). 
PGC- 
	  




mitochondrial biogenesis in many cells types. It is a central transcription effector 
inducing adrenergic action and thermogenesis in adipocytes (Harms and Seale 2013). 
Presently, there has been indirect evidence that WAT adipocytes can acquire brown 
adipocyte characteristics during conditions of cold exposure or catecholamine excess 
(Rosen and MacDougald 2006). Taken together, with increases in both UCP1 and PGC-
 
transcription by TMR, this suggests that it may play an important role in increasing 
the cells capacity for energy expenditure. Our data showing the upregulation of 
mitochondrial biogenesis genes is consistent with our observation in the upregulation of 
PGC-
 
 by TMR. It has been reported that PGC-
 
 stimulates a  large induction in NRF1 
and NRF2 expression (Wu et al. 1999a). TMR may affect the thermogenic program 
causing induction of thermogenic genes, possible through the activation of -adrenergic 
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signaling pathway which leads to upregulation of PGC-  and other thermogenic 
expression in the maturing adipocytes. This higher capacity to utilize energy may be the 
cause our observation in lipid accumulation. It is of interest to note that in mature 3T3-L1 
cells, RES has been shown to increase PGC-
 
 gene expression (Lasa et al. 2012a). 
Resveratrol metabolites, 3G and 4G also increased PGC-  expression, however not in 
significant levels. Collectively, action of thermogenic gene expression may be a potential 
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Figure 3.28 Dose-dependent effect of trans-   -trimethoxyresveratrol (TMR) on 
thermogenic marker gene expression. 3T3-L1 preadipocytes were subjected to 
adipocyte differentiation and an adipogenic cocktail. Cells were incubated in the presence 
of dimethyl sulfoxide (DMSO) or various concentrations of TMR (0, 10, 25, and 50 µM) 
in DMSO for 6 days. The cellular total RNA was extracted and subjected to RT-PCR. 
The mRNA levels of (A) UCP1 and (B) PGC-1 were quantified and normalized with the 
	
   -actin. Data are presented as relative fold induction means ± SEM, 
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3.3.2.7 Beige fat markers 
The development of beige fat, is described as WAT having multi-locular LD 
morphology, high mitochondrial content, and increased expression of specific brown fat 
genes, including UCP1 and PGC-  (Harms and Seale 2013). Beige fat cells also have 
increased ability for thermogenesis. Gene expression of beige-selective gens can help to 
differentiate beige fat cells, from those of BAT and WAT (Wu et al. 2012). Among these 
beige fat markers include transcription factors T-box 1 (Tbx1), transmembrane protein 26 
(Tmem26), and PRD1-BF-RIZ1 homologues domain-containing protein-16 (Prdm16) 
(Rosen and Spiegelman 2014). In order to observe any effect by TMR on the induction of 
these specific beige fat markers, we examined their gene expression. Overall we not that 
TMR has a variable effect (Figure 3.29 A-C). There is a significant induction of Tbx1 
expression by TMR, yet the opposite effect on Tmem26, showing a significant reduction. 
TMR shows no significant difference in the expression Prdm16, however it trends toward 
increasing. T-box genes are essential for the developmental process and has been 
identified as an enriched beige fat marker (Chapman et al. 1996; Harms and Seale 2013). 
With increases in Tbx1, this suggests that TMR may have the ability to induce alterations 
in the cell to increase genes with a phenotype more closely related to beige cells. Tmem26 
is another enriched beige fat marker which is commonly expressed higher in inguinal fat 
compared to brown fat (Wu et al. 2012). Tbx1 and Tmem26 are both beige markers which 
have also been suggested to be present in classical brown tissues. Interestingly, TMR 
showed a reduction in Tmem26, contrasting from a large increase in Tbx1. Currently, the 
determinant of white and brown adipocyte gene programs are not completely understood, 
although analysis of beige fat cells have shown a distinction between the two (Villanueva 
et al. 2013; Wu et al. 2012). Therefore, we tested a third gene that is a key transcription 
factor for both brown and beige fat. Prdm16 ectopic expression is known to convert 
white fat precursors into thermogenic adipocytes which contain UCP1(Harms and Seale 
2013). It has been identified as a co-regulator in differentiation of brown and beige cells, 
with increased expression leading to beige adipocyte development and suppression of 
metabolic disease (Harms et al. 2014). To note, based on the metabolic rate of BAT in 
mice, is was calculated that 40-50 grams of BAT could account for 20% of daily energy 
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expenditure (Rosen and Spiegelman 2014). Although our data shows no significant 
alteration in Prdm16 gene expression, it trends toward increasing with TMR; coupled 
with increased expression of UCP1 may suggest an altered adipocyte metabolism with 
distinctive changes in physiological functions. Taken together, treatment of TMR may 
induce transcriptional cell remodeling in the metabolic efficiency of energy expenditure 
through a higher capacity to burn fat (Figure 3.30). Although more analysis is needed, 
there may be therapeutic potential with TMR due to its involvement of induction of 









Figure 3.29 Dose-dependent effect of trans-   -trimethoxyresveratrol (TMR) on 
beige fat marker gene expression. 3T3-L1 preadipocytes were subjected to adipocyte 
differentiation and an adipogenic cocktail. Cells were incubated in the presence of 
dimethyl sulfoxide (DMSO) or various concentrations of TMR (0, 10, 25, and 50 µM) in 
DMSO for 6 days. The cellular total RNA was extracted and subjected to RT-PCR. The 
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3.4 Summary and conclusions 
The major objectives of this study were to identify the effect of different resveratrol 
metabolites in adipose function in vitro. Due to the fact that RES is quickly metabolized 
in the body, biological activities of its metabolites may be more physiologically relevant 
to study (Lasa et al. 2012a). We singled out TMR as a resveratrol metabolite and 
analogue having specific action in lipid metabolism, specifically for its action in 
adipocyte lipolysis and lipogenesis. Our results demonstrate the first identification of 
TMR acting as an antilipolytic agent in mature adipocytes as well as having action in the 
development of maturing adipocytes. In our study, we were able to establish TMRs 
efficacy with significant, partial inhibition of glycerol release in mature adipocytes, with 
action greater than other resveratrol metabolites examined. TMR was shown to have non-
cytotoxic effects over a range of concentrations extending to safe usage at 50 µM 
displayed by cell viability assays in both pre- and mature adipocytes. Also taken into 
consideration was the stability of TMR in the medium of treated cells. Additionally, we 
determined TMRs rapid uptake into the cell and co-localization with the LD, attributing 
this to TMRs structure and methoxylation, providing a degree of protection and 
enhancing transportation to the cell (Dias et al. 2013). Further studies are needed to fully 
understand the scope of the location of TMR in the cell, but our imaging data provides 
preliminary evidence.  
TMR was able to significantly reduce glycerol release in mature adipocytes in both 
an acute and chronic exposure. Previous research in lab demonstrated a resveratrol 
metabolite, PIC, was able to significantly degrade a primary lipolytic enzyme, ATGL, 
and its co-activator CGI-58 mechanistically through autophagy (intracellular degradation 
of components via lysosome) (Kwon, unpublished). Due to the structural similarity of 
TMR and PIC, we hypothesized that TMR action in lipolysis is also similar. TMR 
demonstrated reduction in protein expression of both ATGL and CGI-58 with acute 
treatment, and to a less extent with a chronic treatment. TMR also demonstrated action in 
slightly blocking the activation of HSL through a slight reduction in phosphorylation. We 
discovered TMRs action in the lipolysis process was greatest seen with an acute 
treatment time with greatest potency with a three hour treatment in basal and stimulated 
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conditions. TMR alters lipolytic gene expression of mature adipocytes which may also be 
a contributor to the reduction in glycerol release and lipolysis. Overall, our data suggests 
that treatment of TMR has the ability to acutely, partially inhibit lipolysis in mature 
adipocytes via possible transcriptional regulation, potential mediation of protein 
degradation or a combination of both. Importantly, treatment of TMR may be a 
therapeutic approach to reduce the level of circulating NEFA in an obesogenic condition 
and help to attenuate the induction of obesity induced insulin resistance and type 2 
diabetes. Additionally, the identification of a dietary antilipolytic compound may also 
help to attenuate the effects of cancer cachexia.  
In an effort to further examine the role of TMR in adipose function, we also studied 
its effect in the development of maturing adipocytes and lipogenesis. Our study suggests 
a role of TMR in lipogenesis and cellular events in early adipocyte development. We 
observed a slight trend toward reduction in LD formation. This data suggests that TMR 
influences the lipogenic pathway and may primarily working through transcriptional 
regulation during differentiation and development of maturing adipocytes. Interestingly, 
TMR increased lipogenic gene expression, although no differences were seen compared 
to the control in lipid accumulation. Further analysis of cellular gene expression showed 
transcriptional increases in catabolic processes and mitochondrial biogenesis. TMR 
significantly upregulates the expression of thermogenic genes, UCP1 and PCG- , 
suggesting an increased capacity for energy expenditure and thermogenesis. Taken 
together, the TMR may play a significant role in transcriptional regulation during 
adipocyte development and may be responsible for redirecting cellular processes toward 
activating energy expenditure in maturing adipocytes. The trend towards reduced lipid 
accumulation and increased lipogenic gene expression can possibly be connected through 
TMRs ability to maintain balance within cellular pathways between energy storage and 
utilization.  
This work in identifying the effect of TMR in maturing preadipocytes may be 
therapeutically important because this type of cell plays a role in obesity development. 
Accordingly, during child development and adolescence, obesity mainly stems from 
induction of hyperplasia, which is suggestive to the differentiation of preadipocytes into 
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mature adipocytes (Eseberri et al. 2013). Furthermore, understanding mechanisms to 
prevent or reduce obesity development may be a strategy to combat this complicated 
disease. Conversely, in adulthood, obesity is primarily of as result of hypertrophy of 
mature adipocytes.  Therefore deeper investigations into the effects on mature adipocyte 
by phytochemicals are needed for the prevention of obesity and associated metabolic 
diseases. A schematic diagram of our proposed mechanism is shown in Figure 3.31 and 
3.32.  
Our study is of significance because it illuminates the role and potential that 
stilbenes can have in overall energy homeostasis. This study suggests the possible role of 
TMR remodeling in adipose tissue to more metabolically active cells. It also provides 
evidence utilizing dietary compounds in modulating adipose lipolysis. Our data 
represents novel suggestions and potential for phytochemicals and their possible 
applications in adipocyte biology. In turn, finding ways to promote the health and welling 
being, especially in an obesogenic diseased state, may lessen the burden of this 
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Figure 3.30 Summary of trans-   -trimethoxyresveratrol (TMR) on functional 
adipocyte gene expression. 3T3-L1 preadipocytes were subjected to adipocyte 
differentiation and an adipogenic cocktail. Cells were incubated in the presence of 
dimethyl sulfoxide (DMSO) or TMR (0 and 50 µM) in DMSO for 6 days. The cellular 
total RNA was extracted and subjected to RT-PCR. The mRNA levels of (A) de novo 
lipogenesis and adipokine marker genes, (B) lipogenic, mitochondrial biogenesis, fatty 
acid oxidation, and thermogenic genes, and (C) beige fat marker genes were quantified 
and 	
      -actin. Data are presented as relative fold 
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Figure 3.31 TMR action in mature adipocyte in vitro.  Acute treatment of TMR in 
mature adipocyte results in reduction of protein expression and overall reduction in 










Figure 3.32 TMR action in development of maturing adipocyte in vitro. Changes 
induced by treatment of TMR in maturing adipocyte during lipogenesis. mRNA 
expression profiles are altered by TMR during development, suggestive of  





CHAPTER 4. FUTURE WORK 
4.1 Limitations of study 
Chapter 3 outlines our results and demonstrates the significant, partial inhibition of 
lipolysis by an acute treatment of TMR. It also shows the effect of TMR in the 
development of maturing adipocytes and the transcriptional remodeling of the adipocyte 
toward increased energy expenditure. However, there are some limitations to the study 
that are important to consider:  
Firstly, the data collected from our experiments were entirely based on in vitro 
results. The 3T3-L1 preadipocyte cell line is widely established, however, due to the fact 
that the results in this study are trying to mimic actual physiological conditions of human 
obesity, the role of prevention, development, and associated metabolic disorders; 
understanding the effect of dietary compounds in vivo is critical. Additionally, our 
experiments were conducted in a tightly controlled atmosphere with one type of cell. To 
be able to have more substantial evidence, a more complex and intricate model such as an 
animal in vivo system, is needed to translate the effects to humans.  
Our study also had technical limitations. Our data in regards to the inhibition of 
lipolysis was done primarily through the level of glycerol release. To further confirm our 
findings, a free fatty acid assay and measurement of TAG, DAG, and MAGs levels 
should also be completed which would account for specific steps in lipolysis that were 
effected. Our study utilized protein expression and analysis to determine the relative level 
of activity in the cell, whereas biochemical enzyme assays to measure the actual activity 
of the enzymes would allow greater specificity in determining the modulation in the cell. 
Furthermore, these types of assays done in primary murine and human adipocytes would 




The lipogenesis piece of our study is restricted to only mRNA gene expression 
analysis and technically limited. Additional confirmatory data with replication and 
reproducibility of the effects we observed will help to strengthen our gene expression 
analysis results. Furthermore, biochemical measurement of the correlating protein levels 
and enzymatic activity of the genes we observed changes in is critical to the proposed 
effect induced transcriptionally by TMR. Other technical assays including mitochondrial 
biogenesis and ATP production techniques would also help connect the data observed in 
the gene profiling and aid to substantiate TMRs effect.  
 Mechanistic pathways are a large part in identifying the beneficial effect of 
phytochemicals. In regards to TMRs effect in lipogenesis, this is a limitation of our study. 
Our data lacks knowledge on specific pathways and how those pathways may be directly 
altered by TMR. One technique in identifying changes in lipogenesis is the utilization of 
radioisotope labeling to track changes in the biosynthesis of TAGs. In addition, SRS 
imaging with labeled glucose is another method that allows the visualization of the 
source and construction of the LD.  
 Finally, the largest drawback of the study is the fact that the data is presented on 
findings based in vitro and should be tested in an in vivo system. TMR showed efficacy at 
50 µM, however this is higher than a physiological condition. Current literature is limited, 
however one studied noted using 4 mg/kg with an intraperitoneal (IP) injection and 10 
mg/kg via oral gavage, however this concentration was fully dissolved in a HP- -CyD 
(Lin and Ho 2009; Lin et al. 2010). Previous research in our lab for PIC utilized 10 
mg/kg/day in an animal model. For animal treatment with TMR, a concentration range up 
to approximately 10-15 mg/kg would be sufficient maximum dose. The bioavailability of 
TMR needs to be considered when choosing a method of treatment. According to the 
study by Lin, they analyzed the pharmacokinetic profile of TMR when given via oral 
gavage and found that it has a short absorption time and prolonged elimination time, with 
a calculated bioavailability F value of 54.9% (Lin and Ho 2009). Taking this into 
consideration, giving the animals an IP injection would allow us to see the direct effect of 
TMR and it would prevent any modifications to the compound. Oral gavage of TMR 
dissolved in a vehicle would give a better understanding of the physiological relevance 
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once ingested. To note, it has been suggested that food may enhance the bioavailability of 
TMR, by stimulated bile secretions (Lin and Ho 2009). In an experimental model that is 
identifying the health benefit of a compound in regards to prevention of obesity, it would 
be most applicable to administer TMR in the diet. Because the nature of this study would 
be a high fat diet-induced obesity model, the increased fat content may help to increase 
the bioavailability of the compound via normal bile secretions. However, stability of 
TMR in the food matrix would need to be examined to ensure its functionality is still 
intact. Depending on the adipose function being analyzed, different animal models should 
be employed. Specific parameters are further discussed in detail below.  
The following outlines experiments and future work that should be done to better 
understand the role of TMR in affecting overall energy homeostasis. 
 
4.2 Future Work: TMR in lipolysis 
Additional research is needed to fully understand mechanistically how TMR acts in 
the cell specific to the lipolytic pathway. Future work needs to be completed both in vitro 
and in vivo studies to characterize TMR in overall modulation of lipolysis.  
Further characterizations of the lipolytic enzymes involved in the lipolysis process 
are needed to gain insight into the overall action of TMR. We mainly examined ATGL, 
the first step in lipolysis, however HSL and MGL are still players in the overall 
progression of lipolysis and their roles maintain specificity. HSL can hydrolyze both 
TAG and DAG, yet it has a higher affinity for DAG (Duncan et al. 2007). We measured 
the phosphorylation of HSL at serine-660; responsible for the LD interfacial activation 
and hydrolysis of DAG (Walther and Farese 2012). However measuring the total level of 
   	
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	  	 
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potential degradation or induction. Similarly, identifying the total protein expression level 
of MGL and perilipin would complete the picture of TMRs modulating role in the entire, 
sequential process of lipolysis. Additionally, other technical measurements need to be 
explored include biochemical enzyme assays order to confirm the action of TMR. 
Biochemical analysis of enzymatic activity of enzymes involved in lipolysis would give a 
clear evidence to the level TMR modulates this process.  
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Our results lack the knowledge and specificity of how possible enzymatic 
degradation occurs: through autophagy or proteasome proteolysis. Our lab has previously 
demonstrated that degradation of ATGL by PIC is not proteasome-dependent, but 
dependent on autophagy and occurs through an autophagy pathway, via the use of 
different inhibitors. Macroautophagy is a lysosomal degradative pathway present in cells 
and is responsible for degrading cytosolic organelles and protein aggregates which are 
too large for proteasome degradation. Autophagy is a highly regulated process in which 
whole organelles and regions of cytoplasm are sequestered inside an enveloping double-
membrane structure termed, autophagosome, which translocates to lysosomes for fusion 
and content degradation (Lee et al. 2010; Singh et al. 2009). Proteolysis involves 
proteases which hydrolyze peptide bonds and then free amino acids are released 
(Glickman and Ciechanover 2002). This occurs under different physiological 
circumstances and allows the cell to accommodate to changes and adapt to its 
environment (Ciechanover 1994; Glickman and Ciechanover 2002). TMRs apparent 
reduction of ATGL and CGI-58 is done through an unknown mechanism, and identifying 
how TMR works would further our knowledge of its modulation, but also increase 
understanding in the markers and regulation of the machinery involved. We also 
observed transcriptional changes by TMR with an acute treatment. This suggests rapid 
turnover in the cell, however this would need to be confirmed through additional 
biochemical analysis experiments.   
The most critical future experiment is to utilize our results and correlate them into 
an in vivo system. It would be advantageous to conduct primary cell culture before 
entering into an in vivo study. This would be a critical step to get a more accurate picture 
of how cells would respond. Testing the efficacy of TMR in both murine and human 
primary cells would be supportive data before taking on an animal model. An animal 
model testing TMRs effect in lipolysis would consist of approximately 16 week old male 
C57B/6J mice that are obese and continued to be fed a high fat diet (60% of calories from 
fat) (HFD) for 1 week prior to treatment. Due to the fact we saw that TMR is most 
effective with an acute treatment, with an in vivo model, this correlates to about 2-4 
weeks of treatment. Two groups (n=8) should be fed as followed: HFD and HFD + 10 
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mg/kg/day TMR. In this treatment mice should have access to water and food ad libitum. 
Body weight and food intake should be recorded about every 3rd day, as well as blood 
samples to measure basal glycerol release, FFA, TAG, and glucose levels. Physiological 
and biochemical parameters after sacrifice should be done upon collection of all tissues, 
including but not limited to, histology, gene profiling, and immunoblot analysis. 
 
4.3 Future Work: TMR in lipogenesis 
We were able to observe that TMR increased catabolic and thermogenic gene 
expression, however, our study was limited to only gene profiling in vitro. Further 
biochemical and proteomic analysis is needed and additional focus on signaling pathways 
involved in observed upregulation.  
It would be beneficial to collect confirmatory data as well as test other genes 
involved in lipogenesis, catabolic processes, and include gene expression that is specific 
to beige fat markers. As previously described, beige cells in murine WAT are defined by 
their morphology, high mitochondrial content, and expression a core set of brown fat 
genes (Harms and Seale 2013). Our data lacks biochemical analysis of the effects 
obtained with gene expression. Therefore, analyzing in depth a wider range of genes and 
correlating proteomic analysis and utilizing enzymatic activity assays would elucidate 
TMRs overall effect during the development of the cell, and would also indicate any 
metabolic switch. Additionally, techniques involving mitochondrial biogenesis, 
respiration, and ATP production need to be investigated to confirm our gene expression 
analysis. 
Further investigation in the location and effect of TMR during the development 
stage of maturing adipocytes is needed. Deuterium-labeled glucose added into the 
medium during the early stages of differentiation and photographed with SRS imaging 
would allow us to visualize the progression of lipid droplet formation and the source of 
energy utilized. This assay would give us a better understanding of how TMR is 
influencing cell during growth and de novo lipogenesis. Additionally, radioisotope 
labeling of FA is another technique that would allow detection of direct pathway changes. 
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knowledge of its therapeutic potential.  
Analyzing the effect of TMR in vivo is imperative. Investigating the remodeling 
role of TMR in vivo would be more applicable for interpretation of physiological 
conditions and human comparison. Examining the role of TMR treatment during the 
development of young mice in a HFD-obesity-induced model, would allow us to 
critically analyze its effect. 3 week old male C57B/6J mice with three groups (n=8) fed as 
HFD, HFD + low dose (3 mg/kg/day TMR), and HFD + high dose (15 mg/kg/day TMR). 
During the experimental period, mice should have access to water and food ad libitum. 
Body weight and food intake will be measured every 3 days with all groups followed for 
approximately 4-6 weeks, around when potential weight diverges are seen for at least 1 
week. If significant change in body weight does not occur, dosages may need to be 
adjusted. Fecal samples will be collected for 1 week and respiratory exchange ratio will 
be analyzed. To determine a potential energy expenditure changes and increased health of 
adipose tissue of TMR, specific biochemical parameters associated with obesity 
development should be measured including serum indicators, gene profiles, and protein 
expression levels in different tissues to show the critical impact on adipogenesis and 
lipogenesis. Other tests should be completed not exclusive to glucose tolerance test, 
serum levels of triglyceride, glucose, insulin, glycerol, and FFA. Additionally, adipose 
tissue, liver, kidney, intestines and other major tissues should be collected, weighed with 
histology, PCR, and immunoblot analysis measured along with other biochemical 
analysis, and measurements specific to mitochondrial biogenesis and thermogenesis. 
Mitochondrial uncoupling has been associated as means of weight-loss therapy and 
increasing the activity of either brown fat, beige fat, or both has large potential for the 
treatment of obesity and metabolic disease by dietary compounds (Harms and Seale 
2013). This model would be representative of a therapeutic treatment during adolescent 
development and growth, in which we could identify any alteration in overall energy 





Collectively, our study elucidates the beneficial activities of dietary compounds, 
such as TMR, in the context of adipose function. Our data represents foundational work 
that can be expanded through future studies, including further investigations not 
mentioned and those mentioned above. In the future, additional in vivo models will help 
to gain new insights into the potential, therapeutic application of TMR and other 
resveratrol metabolites in adipose biology. The over-arching big picture is that this type 
of research can help people who suffer from a variety of metabolic disorders. Identifying 
ways to improve overall health and well-being can improve quality of life and increase 
longevity. The use of phytochemicals as a means to treat conditions has been around for 
centuries, as stated by Hipp  	
   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This idea of food components as a means to improve health is fundamental and needs 
further investigation in discovering the specific pathways and their impact on energy 
balance. A focus on lipid metabolism is extremely relevant to the current health status 
America and application of functional food components may be key. Overall, there is 
vast potential for investigation of dietary components to help reduce the incidence of 
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